WO2023143354A1 - Composé tricyclique et son application - Google Patents
Composé tricyclique et son application Download PDFInfo
- Publication number
- WO2023143354A1 WO2023143354A1 PCT/CN2023/073087 CN2023073087W WO2023143354A1 WO 2023143354 A1 WO2023143354 A1 WO 2023143354A1 CN 2023073087 W CN2023073087 W CN 2023073087W WO 2023143354 A1 WO2023143354 A1 WO 2023143354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- alkyl
- substituted
- cancer
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 420
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 513
- 125000001424 substituent group Chemical group 0.000 claims description 385
- 229910052736 halogen Inorganic materials 0.000 claims description 340
- 150000002367 halogens Chemical group 0.000 claims description 340
- 238000006467 substitution reaction Methods 0.000 claims description 196
- 125000000623 heterocyclic group Chemical group 0.000 claims description 178
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 160
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
- 125000004429 atom Chemical group 0.000 claims description 90
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 86
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 83
- 201000011510 cancer Diseases 0.000 claims description 77
- 150000002148 esters Chemical class 0.000 claims description 70
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 69
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 65
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 62
- 201000010099 disease Diseases 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 59
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- -1 cyano, cyclopropyl Chemical group 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 54
- 125000002837 carbocyclic group Chemical group 0.000 claims description 51
- 239000002207 metabolite Substances 0.000 claims description 51
- 229940002612 prodrug Drugs 0.000 claims description 51
- 239000000651 prodrug Substances 0.000 claims description 51
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 50
- 125000004043 oxo group Chemical group O=* 0.000 claims description 50
- 239000012453 solvate Substances 0.000 claims description 50
- 229910052805 deuterium Inorganic materials 0.000 claims description 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 48
- 125000004432 carbon atom Chemical group C* 0.000 claims description 47
- 230000002018 overexpression Effects 0.000 claims description 42
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 41
- 206010006187 Breast cancer Diseases 0.000 claims description 39
- 208000026310 Breast neoplasm Diseases 0.000 claims description 39
- 208000035475 disorder Diseases 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 35
- 229910003827 NRaRb Inorganic materials 0.000 claims description 32
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 31
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 30
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 24
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 150000001721 carbon Chemical group 0.000 claims description 23
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 22
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
- 206010017758 gastric cancer Diseases 0.000 claims description 22
- 125000004076 pyridyl group Chemical group 0.000 claims description 22
- 201000011549 stomach cancer Diseases 0.000 claims description 22
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 21
- 206010009944 Colon cancer Diseases 0.000 claims description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 21
- 201000010536 head and neck cancer Diseases 0.000 claims description 21
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 21
- 201000005202 lung cancer Diseases 0.000 claims description 21
- 208000020816 lung neoplasm Diseases 0.000 claims description 21
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 20
- 206010060862 Prostate cancer Diseases 0.000 claims description 20
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 19
- 125000004193 piperazinyl group Chemical group 0.000 claims description 19
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 15
- 150000004677 hydrates Chemical class 0.000 claims description 15
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 14
- 206010038389 Renal cancer Diseases 0.000 claims description 14
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 14
- 201000010982 kidney cancer Diseases 0.000 claims description 14
- 201000007270 liver cancer Diseases 0.000 claims description 14
- 208000014018 liver neoplasm Diseases 0.000 claims description 14
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 13
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 13
- 201000004101 esophageal cancer Diseases 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 claims description 12
- 101000597045 Homo sapiens Transcriptional enhancer factor TEF-3 Proteins 0.000 claims description 12
- 101000597035 Homo sapiens Transcriptional enhancer factor TEF-4 Proteins 0.000 claims description 12
- 101000597043 Homo sapiens Transcriptional enhancer factor TEF-5 Proteins 0.000 claims description 12
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 claims description 12
- 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 claims description 12
- 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 claims description 12
- 102100035147 Transcriptional enhancer factor TEF-5 Human genes 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 12
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 12
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 12
- 230000004655 Hippo pathway Effects 0.000 claims description 11
- 206010027406 Mesothelioma Diseases 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 10
- 101000759453 Homo sapiens YY1-associated protein 1 Proteins 0.000 claims description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 8
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010014733 Endometrial cancer Diseases 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 7
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 206010023774 Large cell lung cancer Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 208000009956 adenocarcinoma Diseases 0.000 claims description 7
- 201000011134 adenosquamous prostate carcinoma Diseases 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 7
- 201000007455 central nervous system cancer Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 125000004185 ester group Chemical group 0.000 claims description 7
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 7
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 7
- 201000000020 lung papillary adenocarcinoma Diseases 0.000 claims description 7
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 208000026886 papillary lung adenocarcinoma Diseases 0.000 claims description 7
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 7
- 201000001513 prostate squamous cell carcinoma Diseases 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 201000006134 tongue cancer Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 208000016097 disease of metabolism Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 5
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 150000003254 radicals Chemical group 0.000 claims description 2
- 230000006340 racemization Effects 0.000 claims 9
- 201000008424 adenosquamous lung carcinoma Diseases 0.000 claims 4
- 210000000481 breast Anatomy 0.000 claims 2
- 230000000762 glandular Effects 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 350
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- 239000000243 solution Substances 0.000 description 118
- 235000019439 ethyl acetate Nutrition 0.000 description 117
- 239000012074 organic phase Substances 0.000 description 105
- 239000011541 reaction mixture Substances 0.000 description 101
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 101
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 83
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 77
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
- 238000010898 silica gel chromatography Methods 0.000 description 76
- 238000005481 NMR spectroscopy Methods 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000012043 crude product Substances 0.000 description 45
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 44
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 42
- 239000003208 petroleum Substances 0.000 description 38
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 37
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 36
- 239000012299 nitrogen atmosphere Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 34
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 32
- 239000003480 eluent Substances 0.000 description 30
- 239000000376 reactant Substances 0.000 description 28
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 28
- 238000001308 synthesis method Methods 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- LCFDJWUYKUPBJM-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-indole Chemical compound FC(F)(F)C1=CC=C2NC=CC2=C1 LCFDJWUYKUPBJM-UHFFFAOYSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 238000003756 stirring Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000002808 molecular sieve Substances 0.000 description 22
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000012141 concentrate Substances 0.000 description 20
- 238000002953 preparative HPLC Methods 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 19
- 239000011734 sodium Substances 0.000 description 17
- 230000007704 transition Effects 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 102100023267 YY1-associated protein 1 Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- JAUPUQRPBNDMDT-UHFFFAOYSA-N 2-chloropyridine-3-carbonitrile Chemical compound ClC1=NC=CC=C1C#N JAUPUQRPBNDMDT-UHFFFAOYSA-N 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- 102100027548 WW domain-containing transcription regulator protein 1 Human genes 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- PMIMPBYTPPRBGD-UHFFFAOYSA-N ethyl 2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1Cl PMIMPBYTPPRBGD-UHFFFAOYSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000017945 hippo signaling cascade Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- SDTCGHLDTSGIRR-UHFFFAOYSA-N 3,5-dichloropyrazine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C(Cl)=N1 SDTCGHLDTSGIRR-UHFFFAOYSA-N 0.000 description 2
- CHKLNKWJIDQKFV-UHFFFAOYSA-N 3-chloro-2-fluorobenzonitrile Chemical compound FC1=C(Cl)C=CC=C1C#N CHKLNKWJIDQKFV-UHFFFAOYSA-N 0.000 description 2
- CRRVZRDISHOQQL-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C(F)=C1 CRRVZRDISHOQQL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 description 2
- 102100021437 MOB kinase activator 1A Human genes 0.000 description 2
- 101700059339 MOB1A Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108700021995 Serine-Threonine Kinase 3 Proteins 0.000 description 2
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000012391 XPhos Pd G2 Substances 0.000 description 2
- 108700038175 YAP-Signaling Proteins Proteins 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- RSLSVURFMXHEEU-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[3-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylaniline Chemical compound [Pd+]Cl.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(P(C2CCCCC2)C2CCCCC2)=C1 RSLSVURFMXHEEU-UHFFFAOYSA-M 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- NPCBDQZLUSJKOW-UHFFFAOYSA-M sodium;4-[5-(4-chlorophenyl)-3,4-dihydropyrazol-2-yl]benzenesulfonate Chemical compound [Na+].C1=CC(S(=O)(=O)[O-])=CC=C1N1N=C(C=2C=CC(Cl)=CC=2)CC1 NPCBDQZLUSJKOW-UHFFFAOYSA-M 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000006168 tricyclic group Chemical group 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GKPHNZYMLJPYJJ-UHFFFAOYSA-N 2,3-difluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1F GKPHNZYMLJPYJJ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CNOOTVLHXJLFMF-UHFFFAOYSA-N 2,6,6-trimethyloxaborinane Chemical compound CB1CCCC(C)(C)O1 CNOOTVLHXJLFMF-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- SVAZIMBLBHOVIR-UHFFFAOYSA-N 2-chloro-3-fluoropyridine Chemical compound FC1=CC=CN=C1Cl SVAZIMBLBHOVIR-UHFFFAOYSA-N 0.000 description 1
- MOKUXMQJIYHZCA-UHFFFAOYSA-N 2-chloro-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC=NC(Cl)=C1C#N MOKUXMQJIYHZCA-UHFFFAOYSA-N 0.000 description 1
- KBFVSJVSSMGQJC-UHFFFAOYSA-N 2-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1F KBFVSJVSSMGQJC-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- ATUOLSDAAPMVJJ-UHFFFAOYSA-N 3,5-dichloropyridine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C(Cl)=C1 ATUOLSDAAPMVJJ-UHFFFAOYSA-N 0.000 description 1
- UZHXXRRBFJSFCV-UHFFFAOYSA-N 3,6-dichloropyrazine-2-carbonitrile Chemical compound ClC1=CN=C(Cl)C(C#N)=N1 UZHXXRRBFJSFCV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
- KZAMRRANXJVDCD-UHFFFAOYSA-N 3-chloro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C(Cl)=C1 KZAMRRANXJVDCD-UHFFFAOYSA-N 0.000 description 1
- SDLFAEGTVBPHBK-UHFFFAOYSA-N 3-chloropyrazine-2-carbonitrile Chemical compound ClC1=NC=CN=C1C#N SDLFAEGTVBPHBK-UHFFFAOYSA-N 0.000 description 1
- JLLJPPBGJVCFGG-UHFFFAOYSA-N 3-chloropyridine-4-carbonitrile Chemical compound ClC1=CN=CC=C1C#N JLLJPPBGJVCFGG-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZVJJQADVZUHQTR-UHFFFAOYSA-N 4-chloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=NC=C1C#N ZVJJQADVZUHQTR-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- XVYXWSODSCHHHB-UHFFFAOYSA-N 5-(trifluoromethoxy)-1h-indole Chemical compound FC(F)(F)OC1=CC=C2NC=CC2=C1 XVYXWSODSCHHHB-UHFFFAOYSA-N 0.000 description 1
- QUMDFCREMBCVGP-UHFFFAOYSA-N 5-(trifluoromethyl)-2,3-dihydro-1h-indole Chemical compound FC(F)(F)C1=CC=C2NCCC2=C1 QUMDFCREMBCVGP-UHFFFAOYSA-N 0.000 description 1
- MQOHJAYYYVQBSH-UHFFFAOYSA-N 5-bromo-2-chloropyridine-3-carbonitrile Chemical compound ClC1=NC=C(Br)C=C1C#N MQOHJAYYYVQBSH-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150091877 Ccn2 gene Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 1
- 101000650162 Homo sapiens WW domain-containing transcription regulator protein 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100036193 Protein salvador homolog 1 Human genes 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001409 amidines Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NVWZNEDLYYLQJC-UHFFFAOYSA-N methyl 2-amino-2-methylpropanoate;hydrochloride Chemical compound Cl.COC(=O)C(C)(C)N NVWZNEDLYYLQJC-UHFFFAOYSA-N 0.000 description 1
- JVORYGNKYAXATM-UHFFFAOYSA-N methyl 3-bromo-4-fluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C(Br)=C1 JVORYGNKYAXATM-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 150000002926 oxygen Chemical group 0.000 description 1
- 125000004334 oxygen containing inorganic group Chemical group 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- WCEWCRAPSCLFOV-UHFFFAOYSA-N tributyl-(1-methylimidazol-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN(C)C=N1 WCEWCRAPSCLFOV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the invention belongs to the field of medicinal chemistry, and specifically relates to tricyclic compounds and applications thereof.
- the Hippo signaling pathway regulates many biological processes, including cell proliferation, survival, differentiation, organ size, and tissue homeostasis.
- This pathway consists of a complex cascade of serine/threonine protein kinases, including serine-threonine kinase 3 (STK3) and STK4.
- SAV1 adapter protein salvador homolog 1
- LATS1/2 Upon activation, LATS1/2 binds to MOB kinase activator 1A/B (MOB1A/B) and represses the transcriptional cofactor yes-associated protein (YAP1) and transcriptional coactivators with PDZ-binding motifs (TAZ or WWTR1).
- Hippo pathway When the Hippo pathway is "off,” phosphorylated YAP/TAZ remains cytoplasmic and proteolytic degradation may occur. When the Hippo pathway is "on,” unphosphorylated YAP/TAZ enters the nucleus and binds the transcription factors TEADNA-binding proteins (TEAD1-4). Dysregulation of the Hippo pathway leads to increased activity of YAP/TAZ, which is associated with tumors, hyperproliferation, cell invasion, metastasis, and chemoresistance.
- TEADNA-binding proteins TEAD1-4
- the TEAD transcription factor family is the final effector of the Hippo pathway, which regulates the expression of target genes (Kras, Braf, Ctgf, Cyr6, Axl, Myc, etc.) ), which in turn mediate tumor growth, metastasis, and tissue homeostasis.
- target genes Kras, Braf, Ctgf, Cyr6, Axl, Myc, etc.
- TEAD is highly expressed in a variety of solid tumors, including prostate cancer, gastric cancer, breast cancer, germ cell tumors, squamous cell carcinoma of the head and neck, and renal cell carcinoma. Due to its high correlation with clinicopathological parameters of human malignancies, TEAD can be used as a prognostic biomarker in solid tumors.
- the Hippo pathway is an important anti-tumor target discovered in the past decade. Compared with regulators targeting the upstream of the Hippo signaling pathway, inhibitors targeting TEAD-YAP may be more effective and directly correct the dysregulated Hippo signaling pathway,
- One aspect of the present application relates to a class of compounds capable of binding to TEAD and acting as TEAD inhibitors. Another aspect of the application relates to processes for the preparation of the compounds described herein. Still another aspect of the present application relates to a pharmaceutical composition comprising the compound of the present invention as an active ingredient, and the clinical application of the compound or the pharmaceutical composition of the present invention for tumor treatment.
- the Ao ring is selected from 5-6 membered heteroaryl groups, 5-6 membered heterocyclic groups, and phenyl groups, and the Ao ring is optionally substituted by 1-3 substituents selected from Rx, Ry, Rz, Rm; preferably Preferably, the Ao ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group, 6-membered saturated heterocyclic group, phenyl, pyridyl, and the Ao ring is optionally replaced by 1-3 members selected from Rx, Ry, Substituents of Rz and Rm are substituted; more preferably, the Ao ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group, 6-membered saturated heterocyclic group, phenyl, pyridyl, and the 5-membered heteroaryl
- the group contains 2-4 heteroatoms selected from N, O, S, and the Ao ring is optionally substituted by 1-3 substitu
- the Ao ring is selected from a 5-membered heteroaryl group, the Ao ring is optionally substituted by Rx,
- the Ao ring is optionally substituted by Ry, Rz and Rm;
- the Ao ring is optionally substituted by Ry and Rm;
- the Ao ring is optionally substituted by Rz;
- the Ao ring is selected from thiomorpholinyl, tetrahydrothiopyranyl, phenyl, and pyridyl, the Ao ring is optionally substituted by 1-2 substituents selected from Rz and Rm ;
- the Ao ring is selected from a 5-membered heteroaryl group, a 5-membered unsaturated heterocyclic group,
- the 5-membered heteroaryl is selected from The 5-membered unsaturated heterocyclic group is selected from And meet any of the following conditions (1)-(3):
- the Ao ring is selected from a 5-membered heteroaryl group, the Ao ring is optionally substituted by Rx,
- the Ao ring is optionally substituted by Ry, Rz and Rm;
- the Ao ring is optionally substituted by Ry and Rm;
- the Ao ring is optionally substituted by Rz;
- the Ao ring is selected from thiomorpholinyl, tetrahydrothiopyranyl, phenyl, and pyridyl, the Ao ring is optionally substituted by 1-2 substituents selected from Rz and Rm ;
- Ra, Rb, and Rc are each independently selected from H, C1-C6 alkyl, cyano, C3-C6 cycloalkyl, or Ra, Rb and the carbon atoms connected to them together form azetidine, and
- the azetidine is optionally substituted by a hydroxyl group; preferably, Ra, Rb, and Rc are each independently selected from H, methyl, cyano, cyclopropyl, or Ra, Rb and their joint
- the carbon atoms are taken together to form an azetidine, and the azetidine is optionally substituted with a hydroxyl group;
- Rx is selected from hydroxyl, methyl,
- Ry is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxyl, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by 1-6 deuterium, C3- C1-C6 alkyl substituted by C6 cycloalkyl, C1-C6 alkyl substituted by C6-C10 aryl, C1-C6 alkyl substituted by C6-C10 aryl, Substituted C1-C6 alkyl, 4-6 membered saturated heterocyclic group; preferably, Ry is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxyl, C1-C6 substituted by 1-6 halogen Alkyl, C1-C6 alkyl substituted by 1-6 deuterium, C1-C6 alkyl substituted by C3-C6 cycloalkyl, C1-C6 alkyl substituted by C6-C10
- Rz is selected from C1-C6 alkyl, halogen, Preferably, Rz is selected from methyl, Br, Or, Ry, Rz and their common carbon atoms together form a 4-6 membered saturated carbocyclic ring, a 4-6 membered saturated heterocyclic ring; or preferably, Ry, Rz and their common connected carbon atoms form a 4-6 membered saturated carbocyclic ring, 4-6 membered saturated heterocyclic ring, the 4-6 membered saturated heterocyclic ring contains 1 heteroatom; or more preferably, Ry, Rz and their common carbon atoms together form Cyclobutane, cyclopentane, cyclohexane, piperidine, tetrahydropyran; or most preferably, Ry, Rz and together with the carbon atoms to which they are commonly attached, form Wherein, the 1' carbon atom is a carbon atom connected to Ry and Rz; Rm is an oxo group;
- the Ao ring and its optional substituents, taken as a whole, are selected from the following:
- Bo rings are selected from: It is optionally substituted with 1-3 substituents selected from: thiopentafluoride, -OH, C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1 -6 halogen substituted C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkoxy, halogen, nitro, cyano, amino;
- the above It is optionally substituted with 1-2 substituents selected from the group consisting of: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkane Base, 1-6 halogen substituted C1-C6 alkoxy, halogen; more preferably, the above Optionally substituted with 1-2 substituents selected from: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl , 1-6 halogen substituted C1-C6 alkoxy, halogen; or the above Optionally substituted by 1-2 substituents selected from: C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkyl, halogen;
- substitution positions of the substituents on it are: 2-position mono-substitution, 3-position mono-substitution, 5-position mono-substitution, 4-, 5-position double substitution, 5-, 6-position double substitution, 2-, 5-position - double substitution, 3-, 5-position double substitution;
- the substitution positions of the substituents on it are 3-position mono-substitution and 5-position mono-substitution;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 6-position monosubstituted;
- the substitution position of the substituent on it is 5-position or 6-position single substitution or double substitution;
- substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubsti
- Bo ring is selected from:
- the Co ring is selected from 5-membered heteroaryl ring, 6-membered partially unsaturated heterocyclic ring; preferably, the 5-membered heteroaryl ring is selected from Preferably, the 6-membered partially unsaturated heterocycle is
- a 10 , A 20 , A 30 , A 40 are independently selected from: N, CH, wherein at most 3 are N;
- L is selected from direct bonds, NH, O, S; preferably, L is selected from direct bonds, NH;
- Ro is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C5 heteroaryl, C1-C6 Alkoxy, C1-C6 alkoxy substituted by hydroxy, C1-C6 alkoxy substituted by 5-6 membered heteroaryl, C3-C5 Heterocyclyloxy, carboxyl (-COOH), ester (-CO-O-C1-C6 alkyl), hydroxyl, amino, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen Substituted C1-C6 alkyl, C1-C6 alkyl substituted by cyano, C1-C6 alkoxy substituted by 1-6 halogen, halogen, cyano, nitro, oxo, C2-C6 alkene C1-C6 alkyl group, C1-C6 alky
- Ro is selected from: oxo, -OCH 3 , -CH 3 , -F, -Cl, -CN, -OH, -NH 2 , -COOH, -COOCH 3 , -CH 2 CH 3 , -CF 3 , -CHF 2 , or two Ro together with the atoms to which they are attached:
- the Ao ring and its optional substituents as a whole are selected from Preferably, the Ao ring and its optional substituents as a whole are selected from Most preferably, the Ao ring and its optional substituents, taken as a whole, are
- the Aoc ring and its optional substituents as a whole are selected from Preferably, the Aoc ring and its optional substituents as a whole are selected from Most preferably, the Aoc ring and its optional substituents as a whole are
- the definition of the Co ring is the same as that of the Co ring in the above formula O; the definition of Ro is the same as the definition of Ro in the above formula O.
- the definition of the Aoc ring and its optional substituents as a whole is the same as the definition of the Aoc ring and its optional substituents in the above formula Oc; the definitions of A 10 , A 20 , A 30 , and A 40 are the same as those in the above formula The definitions of A 10 , A 20 , A 30 , and A 40 in O are the same; the definition of Ro is the same as that of Ro in the above formula O.
- the above-mentioned compound of formula O is the following formula O-1:
- the definition of Ao ring is the same as the definition of Ao ring in the above-mentioned formula O;
- the definition of Bo ring is the same as the definition of Bo ring in the above-mentioned formula O;
- the definition of Co ring is the same as the definition of Co ring in the above-mentioned formula O;
- the definition is the same as the definition of L 0 in the above formula O;
- Ro 11 , Ro 12 and the atoms connected to them together form a C6-C10 aromatic ring, a partially unsaturated C5-C6 carbocyclic ring, a partially unsaturated 5-6 membered heterocyclic ring or 5-6 membered heteroaromatic ring, wherein the partially unsaturated C5-C6 carbocyclic ring, partially unsaturated 5-6 membered heterocyclic ring or 5-6 membered heteroaromatic ring is optionally replaced by 1-6 members selected from halogen and deuterium group; preferably, Ro 11 ,
- Ro 11 , Ro 12 and the atoms attached to them together form:
- A1 ring is the same as the definition of Ao ring in the above formula O;
- B1 ring is the same as the definition of Bo ring in the above formula O;
- L 1 is the same as the definition of L 0 in the above formula O;
- a 1 , A 2 , A 3 and A 4 are independently selected from: N, CH, and at most 3 of them are N;
- R 1 is the same as the definition of Ro in the above formula O.
- a 1c ring and its optional substituents as a whole have the same definition as the Aoc ring and its optional substituents in the above formula Oc as a whole;
- a 1 , A 2 , A 3 , and A 4 are independently selected from : N, CH, wherein at most 3 are N;
- the definition of R1 is the same as the definition of R1 in the above formula I.
- the A11 ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group,
- the 5-membered heteroaryl is selected from The 5-membered unsaturated heterocyclic group is selected from And meet any one of the following conditions (1)-(2):
- the A11 ring is selected from a 5-membered heteroaryl group, the A11 ring is optionally substituted by Rx,
- the A11 ring is selected from a 5-membered unsaturated heterocyclic group, the A11 ring is optionally substituted by Rm or Rz, or optionally substituted by Ry and Rm;
- Rx is selected from methyl
- Ry is a methyl group; Rz is selected from halogen (preferably Br); Rm is an oxo group;
- ring A11 and its optional substituents taken as a whole, are selected from the following:
- Ring B11 is selected from: It is optionally substituted with 1-3 substituents selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1-6 halogen substituted C1-C6 Alkyl, 1-6 halogen substituted C1-C6 alkoxy, halogen, amino;
- the above Optionally substituted with 1-2 substituents selected from: 1-6 halogen substituted C1-C6 alkyl, C3-C4 cycloalkyl, 1-6 halogen substituted C1-C6 alkane Oxygen, amino;
- the B11 ring is selected from:
- R 11 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl, C1-C6 Alkoxy, halogen, cyano, nitro;
- R 11 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl , halogen, cyano; further preferably, R 11 is selected from: -CH 3 , -F, -Cl, -CN; more preferably, R 11 is located in ring The position on is selected from: 1-position, 2-position, 3-position, 4-position.
- the above-mentioned compound of formula I-1 is the following formula I-1c:
- a 11c ring and its optional substituents as a whole are selected from Preferably, the A 11c ring and its optional substituents as a whole are selected from More preferably, the A 11c ring and its optional substituents, taken as a whole, are
- the definition of R 11 is the same as the definition of R 11 in the above formula I-1.
- the A12 ring is selected from a 5-membered heteroaryl group, a 5-membered unsaturated heterocyclic group,
- the 5-membered heteroaryl is selected from
- the 5-membered unsaturated heterocyclic group is selected from And meet any of the following conditions (1)-(3):
- the A12 ring is selected from a 5-membered heteroaryl group, the A12 ring is optionally substituted by Rx,
- Ring A12 is selected from When, the A12 ring is optionally substituted by 1-2 substituents selected from Rz and Rm;
- Rx is selected from hydroxyl
- Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3
- Rz is selected from methyl, Alternatively, Ry, Rz, and the carbon atoms connected to them together form Wherein, the 1' carbon atom is a carbon atom connected to Ry and Rz; Rm is an oxo group;
- ring A12 and its optional substituents taken as a whole, are selected from the following:
- the B12 ring is selected from: It is optionally substituted with 1-3 substituents selected from: thiopentafluoride, -OH, C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1 -6 halogen substituted C1-C6 alkyl, halogen, nitro, cyano, amino;
- substituents are selected from: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen;
- substitution positions of the substituents on it are: 2-position mono-substitution, 3-position mono-substitution, 5-position mono-substitution, 4-, 5-position double substitution, 5-, 6-position double substitution, 2-, 5-position - double substitution, 3-, 5-position double substitution;
- the substitution positions of the substituents on it are 3-position mono-substitution and 5-position mono-substitution;
- substitution position is 5-position monosubstitution;
- substitution position of the substituent on it is 6-position monosubstituted;
- substitution position of the substituent on it is 5-position or 6-position single substitution or double substitution;
- substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position or 6-position single substitution or double substitution;
- substitution position of the substituent on it is 5-position monosubstituted;
- substitution position of the substituent on it is 5-position monosubstituted;
- the B12 ring is selected from:
- R 12 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl, C1-C6 Alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by amino, C1-C6 alkoxy substituted by 1-6 halogen, C1-C5 heteroaryl, C1-C6 alkoxy, C1-C6 alkoxy substituted by hydroxy, C1-C6 alkoxy substituted by 5-6 membered heteroaryl, C3-C5 heterocyclyloxy, carboxyl (-COOH), ester Group (-CO-O-C1-C6 alkyl), hydroxyl, amino, halogen, cyano, C2-C6 alkenyl, C1-C6 alkyl substituted by C6-C10 aryl, 5-6 membered heterocycl
- the above-mentioned compound of formula I-2 is the following formula I-2c:
- a 12c ring and its optional substituents as a whole are selected from:
- the A 12c ring and its optional substituents, taken as a whole, are selected from:
- the A 12c ring and its optional substituents, taken as a whole, are selected from:
- the definition of A 12 , A 22 , A 32 , A 42 is the same as the definition of A 12 , A 22 , A 32 , A 42 in the above formula I-2;
- the definition of R 12 is the same as the definition of R 12 in the above formula I-2 same.
- the above-mentioned compound of formula I is the following formula I-3:
- A13 ring is selected from 5-6 membered heteroaryl, 5-6 membered heterocyclic group, phenyl, and A13 ring is optionally substituted by 1-3 substituents selected from Rx, Ry, Rz, Rm ;
- the A13 ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group, 6-membered saturated heterocyclic group, phenyl, pyridine group, and A13 ring is optionally substituted by 1-3 substituents selected from Rx, Ry, Rz, Rm; more preferably, A13 ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group, 6-membered saturated heterocyclic group, phenyl, pyridyl, the 5-membered heteroaryl group contains 2-4 heteroatoms selected from N, O, S, and the A13 ring is optionally replaced by 1-3 selected from Rx , Ry, Rz, Rm are substituted by substituents;
- the A13 ring is selected from a 5-membered heteroaryl group, the A13 ring is optionally substituted by Rx,
- the A13 ring is optionally substituted by Ry and Rm;
- the A13 ring is selected from thiomorpholinyl, tetrahydrothiopyranyl, phenyl, and pyridyl, the A13 ring is optionally substituted by 1-2 substituents selected from Rz and Rm ;
- the A13 ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group,
- the 5-membered heteroaryl is selected from The 5-membered unsaturated heterocyclic group is selected from And meet any of the following conditions (1)-(3):
- the A13 ring is selected from a 5-membered heteroaryl group, the A13 ring is optionally substituted by Rx,
- the A13 ring is optionally substituted by Ry and Rm;
- the A13 ring is selected from thiomorpholinyl, tetrahydrothiopyranyl, phenyl, and pyridyl, the A13 ring is optionally substituted by 1-2 substituents selected from Rz and Rm ;
- Ra, Rb, and Rc are each independently selected from H, C1-C6 alkyl, cyano, C3-C6 cycloalkyl, or Ra, Rb and the carbon atoms connected to them together form azetidine, and The azetidine is optionally substituted by a hydroxyl group; preferably, Ra, Rb, and Rc are each independently selected from H, methyl, cyano, cyclopropyl, or Ra, Rb and their joint carbon atoms together to form azetidine, and said azetidine is optionally substituted by hydroxyl;
- Rx is selected from hydroxyl, methyl,
- Ry is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxyl, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by 1-6 deuterium, C3- C1-C6 alkyl substituted by C6 cycloalkyl, C1-C6 alkyl substituted by C6-C10 aryl, C1-C6 alkyl substituted by C6-C10 aryl, Substituted C1-C6 alkyl, 4-6 membered saturated heterocyclic group; preferably, Ry is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxyl, C1-C6 substituted by 1-6 halogen Alkyl, C1-C6 alkyl substituted by 1-6 deuterium, C1-C6 alkyl substituted by C3-C6 cycloalkyl, C1-C6 alkyl substituted by C6-C10
- Rz is selected from C1-C6 alkyl, halogen, Preferably, Rz is selected from methyl, Br,
- Ry, Rz and their common carbon atoms together form a 4-6 membered saturated carbocyclic ring, a 4-6 membered saturated heterocyclic ring; or preferably, Ry, Rz and their common connected carbon atoms form a 4-6 membered saturated carbocyclic ring, 4-6 membered saturated heterocyclic ring, the 4-6 membered saturated heterocyclic ring contains 1 heteroatom; or more preferably, Ry, Rz and their common carbon atoms together form Cyclobutane, cyclopentane, cyclohexane, piperidine, tetrahydropyran;
- Ry, Rz and together with their common carbon atoms form Wherein, the 1' carbon atom is the carbon atom connected with Ry and Rz;
- Rm is an oxo group
- the A13 ring and its optional substituents as a whole are selected from the following:
- the A13 ring is selected from: and said optionally by Rm Substituted, or optionally substituted by Ry and Rm; wherein, Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 ; Rm is an oxo group;
- ring A13 and its optional substituents taken as a whole, are selected from the following:
- Ring B13 is selected from: It is optionally substituted with 1-2 substituents selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, C1-C6 substituted with 1-6 halogen Alkyl, halogen, amino;
- the above Optionally substituted by 1-2 substituents selected from: C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkyl;
- the B13 ring is selected from:
- L is selected from direct bond, NH, O, S; preferably, L is selected from direct bond, NH;
- R 13 is selected from: C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkoxy substituted by 1-6 halogen, cyano Substituted C1-C6 alkyl, halogen, cyano, amino, C1-C6 alkyl substituted by amino, C2-C6 alkenyl, 5-6 membered saturated heterocyclic group substituted by C1-C3 alkyl (preferably C1-C3 alkyl substituted 6-membered saturated heterocyclic group); or two R 13 , the atoms connected to them together form a C6-C10 aromatic ring, partially unsaturated C5-C6 carbocyclic ring, partially unsaturated 5-6-membered Heterocyclic ring or 5-6 membered heteroaryl ring, wherein the partially unsaturated C5-C6 carbocyclic ring, partially unsaturated 5-6 membered heterocyclic ring
- R 13 is selected from: -OCH 3 , -CH 3 , -CH 2 CH 3 , -F, -Cl, -CN, -CF 3 , -CHF 2 , -NH 2 , or two R 13 together with the atoms they are attached to form: More preferably, the position of R 13 on the ring is selected from: A 23 position, A 33 position;
- a 13 , A 23 , A 33 , and A 43 are independently selected from: N, CH, and only 2 of them are N, and the rest are CH;
- a 13 , A 23 , A 33 , A 43 are selected from the following combinations:
- Both A 13 and A 43 are N, and both A 23 and A 33 are CH;
- Both A 33 and A 43 are N, and both A 13 and A 23 are CH;
- Both A 23 and A 43 are N, and both A 13 and A 33 are CH.
- the above-mentioned compound of formula I-3 is the following formula I-3c:
- a 13c ring and its optional substituents as a whole are selected from:
- the A 13c ring and its optional substituents, taken as a whole, are selected from:
- the A 13c ring and its optional substituents, taken as a whole, are selected from:
- a 13 , A 23 , A 33 , A 43 is the same as the definition of A 13 , A 23 , A 33 , A 43 in the above formula I-3; the definition of R 13 is the same as the definition of R 13 in the above formula I-3 same.
- Y 14 is selected from N, CH;
- A14 ring is selected from 5-membered heteroaryl, 5-membered unsaturated heterocyclic group, and the 5-membered heteroaryl is selected from The 5-membered unsaturated heterocyclic group is selected from And meet any one of the following conditions (1)-(2):
- the A14 ring is selected from a 5-membered heteroaryl group, the A14 ring is optionally substituted by Rx,
- Rx is selected from hydroxyl
- Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 , Rz is selected from methyl,
- Ry, Rz, and the carbon atoms connected to them together form Wherein, the 1' carbon atom is the carbon atom connected with Ry and Rz;
- Rm is an oxo group
- ring A14 and its optional substituents, taken as a whole, are selected from the following:
- Ring B14 is selected from: It is optionally substituted with 1-3 substituents selected from: thiopentafluoride, -OH, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1 -C6 alkyl, halogen, nitro, cyano, amino, C3-C4 cycloalkyl,;
- the above It is optionally substituted with 1-2 substituents selected from the group consisting of: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkane base, halogen;
- the substitution positions of the substituents on it are: 2-position mono-substitution, 3-position mono-substitution, 5-position mono-substitution, 4-, 5-position double substitution, 5-, 6-position double substitution, 2-, 5-position - double substitution, 3-, 5-position double substitution;
- the substitution positions of the substituents on it are 3-position mono-substitution and 5-position mono-substitution;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 6-position monosubstituted,
- the substitution position of the substituent on it is 5-position or 6-position single substitution or double substitution;
- the substitution position of the substituent on it is 5-position monosub
- the B14 ring is selected from:
- R 14 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl, C1-C6 Alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by amino, C1-C6 alkyl substituted by cyano, C1-C6 substituted by 1-6 halogen Alkoxy, C1-C5 heteroaryl, C1-C6 alkoxy, C1-C6 alkoxy substituted by hydroxy, C1-C6 alkoxy substituted by 5-6 membered heteroaryl, C3-C5 heterocycle Oxygen group, carboxyl group (-COOH), ester group (-CO-O-C1-C6 alkane base), hydroxyl, amino, halogen, cyano, C2-C6 alkenyl, C1-C6 alkyl substitute
- R is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyls on N, carbamoyl substituted by 1-2 C1-C6 alkyls on N, pyridyl C1-C6 Alkoxy, hydroxyl substituted C1-C6 alkoxy, C3 heterocyclyloxy, carboxyl (-COOH), ester (-CO-O-C1-C6 alkyl), hydroxyl, amino, C1-C6 alkane Oxygen, C1-C6 alkyl, C1-C6 alkyl substituted by 1-3 halogen, C1-C6 alkyl substituted by amino, C1-C6 alkyl substituted by cyano, halogen, cyano, C2 -C6 alkenyl, C1-C6 alkyl substituted by phenyl, tetrahydropyrrolyl, piperazinyl, wherein C3 heterocyclic group is optionally substituted by
- R 14 is selected from: -OH, -NH 2 , -COOH, -COOCH 3 , -CH 3 , -CH 2 CH 3 , -F, -Cl, -CN, -CHF 2 , -CF 3 , or two R14 together with the atoms they are attached to form:
- the A111 ring is selected from 5-membered heteroaryl groups and 5-membered unsaturated heterocyclic groups
- the 5-membered heteroaryl groups are selected from
- the 5-membered unsaturated heterocyclic group is selected from And meet any one of the following conditions (1)-(2):
- the A111 ring is selected from a 5-membered heteroaryl group, the A111 ring is optionally substituted by Rx,
- the A111 ring is selected from a 5-membered unsaturated heterocyclic group, the A111 ring is optionally substituted by Rm or Rz, or optionally substituted by Rm and Ry;
- Rx is selected from methyl
- Ry is selected from methyl
- Rz is selected from halogen (preferably Br);
- Rm is an oxo group;
- ring A111 and its optional substituents, taken as a whole are selected from the following: More preferably, ring A111 and its optional substituents as a whole are selected from Further preferably, ring A111 and its optional substituents as a whole are selected from Most preferably, the A111 ring and its optional substituents, taken as a whole, are
- the B111 ring is selected from: It is optionally substituted with 1-3 substituents selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, 1-6 Halogen substituted C1-C6 alkoxy, halogen; preferably, the above Optionally substituted by 1-2 substituents selected from: 1-6 halogen substituted C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkoxy; more preferably, the above Optionally substituted by 1-2 substituents selected from: -CF 3 , -OCF 3 ;
- the B111 ring is selected from: preferably
- the A112 ring is selected from a 5-membered heteroaryl group, a 5-membered unsaturated heterocyclic group,
- the 5-membered heteroaryl is selected from The 5-membered unsaturated heterocyclic group is selected from And meet any one of the following conditions (1)-(2):
- the A112 ring is selected from a 5-membered heteroaryl group, the A112 ring is optionally substituted by Rx,
- the A112 ring is selected from a 5-membered unsaturated heterocyclic group, the A112 ring is optionally substituted by Rm or Rz, or optionally substituted by Ry and Rm;
- Rx is selected from methyl
- Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 , Rz is selected from halogen (preferably Br), Rm is an oxo group;
- the A112 ring and its optional substituents, taken as a whole, are selected from the following:
- B112 rings are selected from: It is optionally substituted with 1-3 substituents selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, 1-6 Halogen substituted C1-C6 alkoxy, halogen; preferably, the above Optionally substituted by 1-2 substituents selected from: 1-6 halogen substituted C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkoxy; more preferably, the above Optionally substituted by 1-2 substituents selected from: -CF 3 , -OCF 3 ; most preferably, ring B112 is:
- R 112 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl, C1-C6 Alkoxy, halogen, cyano, nitro, amino; more preferably, R 112 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyls on N, 1-2 C1- on N C6 alkyl substituted carbamoyl, C1-C6 alkyl, halogen, cyano; further preferably, R is selected from: -CH 3 , -CH 2 CH 3 , CF 3 , -F, -Cl, -CN;
- R 112 is located in ring
- the position on is selected from: 1-position, 2-position, 3-position, 4-position.
- the A 112c ring and its optional substituents as a whole are selected from Preferably, the A 112c ring and its optional substituents as a whole are selected from
- R 112 is the same as the definition of R 112 in the above formula I-1-2.
- the A121 ring is selected from 5-membered heteroaryl groups and 5-membered unsaturated heterocyclic groups
- the 5-membered heteroaryl groups are selected from
- the 5-membered unsaturated heterocyclic group is selected from And meet any one of the following conditions (1)-(2):
- the A121 ring is selected from a 5-membered heteroaryl group, the A121 ring is optionally substituted by Rx,
- the A121 ring is optionally substituted by Ry, Rz and Rm;
- the A121 ring is optionally substituted by Ry and Rm;
- the A121 ring is optionally substituted by Rz;
- Rx is selected from hydroxyl
- Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 , Rz is selected from methyl,
- Ry, Rz, and the carbon atoms connected to them together form Wherein, the 1' carbon atom is the carbon atom connected with Ry and Rz;
- Rm is an oxo group
- ring A121 and its optional substituents taken as a whole, are selected from the following:
- the B121 ring is selected from: It is optionally substituted with 1-3 substituents selected from: thiopentafluoride, -OH, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1 -C6 alkyl, halogen, nitro, cyano, amino;
- the above It is optionally substituted with 1-2 substituents selected from the group consisting of: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkane base, halogen;
- substitution positions of the substituents on it are: 2-position mono-substitution, 3-position mono-substitution, 5-position mono-substitution, 4-, 5-position double substitution, 5-, 6-position double substitution, 2-, 5-position - double substitution, 3-, 5-position double substitution;
- the substitution positions of the substituents on it are 3-position mono-substitution and 5-position mono-substitution;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 6-position monosubstituted,
- the substitution position of the substituent on it is 5-position or 6-position single substitution or double substitution;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosubstituted;
- the substitution position of the substituent on it is 5-position monosub
- the B121 ring is selected from:
- R 121 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyl on N, carbamoyl substituted by 1-2 C1-C6 alkyl on N, C1-C6 alkyl, C1-C6 Alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by amino, C1-C6 alkoxy substituted by 1-6 halogen, C1-C5 heteroaryl, C1-C6 alkoxy, C1-C6 alkoxy substituted by hydroxy, C1-C6 alkoxy substituted by 5-6 membered heteroaryl, C3-C5 heterocyclyloxy, carboxyl (-COOH), ester Group (-CO-O-C1-C6 alkyl), hydroxyl, amino, halogen, cyano, C2-C6 alkenyl, C1-C6 alkyl substituted by C6-C10 aryl, 5-6 membered hetero
- R 121 is selected from: aminosulfonyl substituted by 1-2 C1-C6 alkyls on N, carbamoyl substituted by 1-2 C1-C6 alkyls on N, pyridyl C1-C6 Alkoxy, hydroxyl substituted C1-C6 alkoxy, C3 heterocyclyloxy, carboxyl (-COOH), ester (-CO-O-C1-C6 alkyl), hydroxyl, amino, C1-C6 alkane Oxygen, C1-C6 alkyl, C1-C6 alkyl substituted by 1-3 halogen, C1-C6 alkyl substituted by amino, halogen, cyano, C2-C6 alkenyl, C1 substituted by phenyl -C6 alkyl, tetrahydropyrrolyl, piperazinyl, wherein C3 heterocyclyl is optionally substituted by C1-C3 alkyl, tetrahydr
- R 121 is selected from: -OH, -NH 2 , -COOH, -COOCH 3 , -CH 3 , -CH 2 CH 3 , -F, -Cl, -CN, -CHF 2 , -CF 3 , or two R 121 together with the atoms they are attached to form:
- the position of R 121 on the ring is selected from: 1-position, 3-position, 2-position, preferably 3-position, 2-position.
- the A 121c ring and its optional substituents as a whole are selected from:
- the A 121c ring and its optional substituents, taken as a whole are selected from:
- the A 121c ring and its optional substituents, taken as a whole are:
- R 121 is the same as the definition of R 121 in the above formula I-2-1.
- the A122 ring is selected from Preferably, the A122 ring is selected from
- B122 rings are selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are selected from -CF 3 ; further more preferably, the B122 ring is
- the A123 ring is selected from Preferably, the A123 ring is selected from
- B123 rings are selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; More preferably, the substituent is selected from -CF 3 ; further more preferably, the B123 ring is
- the A124 ring is selected from: and said optionally substituted by Rm or optionally substituted by Ry and Rm, the optionally substituted with 1-2 substituents selected from Rz and Rm;
- Ry is a methyl group
- Rz is selected from Rm is an oxo group
- ring A124 and its optional substituents taken as a whole, are selected from the following: More preferably, ring A124 and its optional substituents as a whole are selected from
- B124 rings are selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; More preferably, the substituent is selected from -CF 3 ; further more preferably, the B124 ring is
- ring A125 is the same as the definition of ring A12 in the above formula I-2;
- a 125 , A 225 , A 325 , and A 425 are independently selected from: N, CH, and only one of them is N, and the rest are CH ;
- a 125 , A 225 , and A 325 are CH, and A 425 is N;
- the definition of R 125 is the same as the definition of R 12 in the above formula I-2;
- B125 rings are selected from: It is optionally substituted with 1 substituent selected from: thiopentafluoride, C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; and the above The substitution position of the substituent on it is: 5-position monosubstituted;
- the B125 ring is selected from: which is optionally substituted with 1 substituent selected from: -CF 3 , -Cl, -SF 5 , -CH 3 , -F, -OCH 3 ; and the above
- the substitution position of the substituent on it is: 5-position monosubstituted;
- the B125 ring is selected from: Most preferably, the B125 ring is
- the A131 ring is selected from: and said optionally substituted by Rm, or optionally substituted by Ry and Rm;
- Ry is selected from methyl, -CHF 2 , -CF 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3, -CH 2 CH 2 OH;
- Rm is an oxo group;
- ring A131 and its optional substituents, taken as a whole, are selected from the following:
- ring A131 and its optional substituents, taken as a whole are selected from the following: Most preferably, the A131 ring and its optional substituents, taken as a whole, are selected from:
- the B131 ring is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituent is selected from: C1-C6 alkyl, C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituent is selected from -CF 3 , Further more preferably, the B131 ring is
- L 131 is selected from direct bond, NH, O, S; preferably, L 131 is selected from direct bond, NH; A 131 , A 231 , A 331 , A 431 are independently selected from: N, CH, and only 2 of them is N, and the rest are CH; preferably, A 131 , A 231 , A 331 , and A 431 are selected from the following combinations:
- Both A 131 and A 431 are N, and both A 231 and A 331 are CH;
- Both A 331 and A 431 are N, and both A 131 and A 231 are CH;
- Both A 231 and A 431 are N, and both A 131 and A 331 are CH.
- ring A131c is the same as that of ring A131 in the above formula I-3-1;
- a 131 , A 231 , A 331 , and A 431 are the same as the definitions of A 131 , A 231 , A 331 , and A 431 in the above formula I-3-1.
- the A132 ring is selected from: and said Optionally substituted by Rm, or optionally substituted by Ry and Rm; wherein, Ry is selected from methyl, -CHF 2 , -CF 3 , -CD 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3, -CH 2 CH 2 OH; Rm is an oxo group;
- the A132 ring and its optional substituents, taken as a whole, are selected from the following:
- ring A132 and its optional substituents taken as a whole, are selected from the following: Most preferably, the A132 ring and its optional substituents act as Overall, selected from:
- B132 rings are selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are selected from -CF 3 ; further more preferably, the B132 ring is
- R 132 is selected from: C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkoxy substituted by 1-6 halogen, cyano Substituted C1-C6 alkyl, halogen, cyano, amino, C1-C6 alkyl substituted by amino, C2-C6 alkenyl, 6-membered saturated heterocyclic group substituted by C1-C3 alkyl; or two R 132 , and the atoms connected to them together form a C6-C10 aromatic ring, a partially unsaturated C5-C6 carbocyclic ring, a partially unsaturated 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring, in which a partially unsaturated C5-C6 carbon Ring, partially unsaturated 5-6 membered heterocycle or 5-6 membered heteroaromatic ring are each optionally substituted with 1-6
- R 132 is selected from: -OCH 3 , -CH 3 , -CH 2 CH 3 , -F, -Cl, -CN, -CF 3 , -CHF 2 , -NH 2 , or two R 132 together with the atoms they are attached to form:
- the position of R 132 on the ring is selected from: A 232 position, A 332 position; A 132 , A 232 , A 332 , A 432 are independently selected from: N, CH, and only 2 of them are N , and the rest are CH; preferably, A 132 , A 232 , A 332 , and A 432 are selected from the following combinations: both A 132 and A 432 are N, and both A 232 and A 332 are CH.
- A132c ring is the same as the definition of A132 ring in the above formula I-3-2;
- R 132 is the same as the definition of R 132 in the above formula I-3-2;
- the definition of 432 is the same as that of A 132 , A 232 , A 332 , and A 432 in the above formula I-3-2.
- the definition of the A133 ring is the same as the definition of the A13 ring in the above-mentioned formula I-3; the definition of the B133 ring is the same as the definition of the B13 ring in the above-mentioned formula I- 3 ; Same definition.
- ring A134 is the same as the definition of ring A13 in the above formula I-3; preferably, ring A134 and its optional substituents as a whole are selected from More preferably, the A134 ring and its optional substituents as a whole are selected from:
- the definition of the B134 ring is the same as the definition of the B13 ring in the above formula I-3; preferably, the B134 ring is selected from: It is optionally substituted with 1-2 substituents selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, C1-C6 substituted with 1-6 halogen Alkyl, halogen, amino; more preferably, the above Optionally substituted by 1-2 substituents selected from: C1-C6 alkyl, 1-6 halogen substituted C1-C6 alkyl; more preferably, the above optionally substituted with 1 substituent,
- the substituent is selected from: -CF 3 , Still further preferably, the B134 ring is selected from: Most preferably, the B134 ring is
- R 134 is the same as the definition of R 13 in the above formula I-3; preferably, two R 134 , and the atoms connected to them together form a 5-membered heteroaromatic ring; more preferably, or two R 134 connected to them The atoms of together form:
- ring A135 is the same as the definition of ring A13 in the above formula I-3;
- B135 rings are selected from: It is optionally substituted with 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1-6 halogen substituted C1-C6 alkyl , halogen, amino; and the above The substitution position of the substituent on it is: 5-position monosubstituted;
- R 135 is the same as the definition of R 13 in the above formula I-3;
- a 135 , A 235 , A 335 , and A 435 are independently selected from: N, CH, and only 2 of them are N, and the rest are CH; preferably Specifically, A 135 , A 235 , A 335 , A 435 are selected from the following combinations:
- Both A 135 and A 435 are N, and both A 235 and A 335 are CH;
- Both A 335 and A 435 are N, and both A 135 and A 235 are CH;
- Both A 235 and A 435 are N, and both A 135 and A 335 are CH.
- Ring A2 is selected from: Preferably, the A2 ring is selected from More preferably, ring A2 is selected from
- R 2 is selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1-6 halogen substituted C1-C6 alkyl, halogen, amino; preferably, R 2 is selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, R 2 is -CF 3 ; further more preferably, the position of R 2 is: 5-position monosubstitution.
- the A3 ring is selected from: Preferably, the A3 ring is selected from More preferably, the A3 ring is selected from
- R is selected from: C1-C6 alkyl, C1-C6 alkoxy, C3-C4 cycloalkyl, 1-6 halogen substituted C1-C6 alkyl, halogen, amino; preferably, R is selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, R 3 is -CF 3 ; further more preferably, the position of R 3 is: 5-position monosubstitution.
- the A4 ring is selected from: and said optionally substituted by Rm, or optionally substituted by Ry and Rm;
- Ry is selected from methyl, -CHF 2 , -CF 3 , CD 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 , Rm is an oxo group;
- ring A4 and its optional substituents, taken as a whole are selected from:
- ring A4 and its optional substituents, taken as a whole are selected from:
- ring A4 and its optional substituents, taken as a whole are selected from:
- Ring B4 is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are -CF 3 ; further more preferably, the B4 ring is
- the C4 ring is selected from
- R is selected from: C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkoxy substituted by 1-6 halogen, halogen, cyano group, amino group; or two R 4 , and the atoms connected to them together form a 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring; preferably, R 4 is selected from: C1-C6 alkyl; or two R 4 , the atoms connected to them form a 5-6-membered heterocyclic ring or a 5-6-membered heteroaromatic ring; more preferably, two R 4 , and the atoms connected to them form a 5-6-membered heterocyclic ring; most preferably , two R 4 , together with the atoms they are connected to form:
- the above-mentioned compound of formula IV is the following formula IV-1:
- ring A41 is the same as the definition of ring A4 in the above formula IV;
- Ring B41 is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are -CF 3 ; further more preferably, the B41 ring is A 41 is selected from: O, S.
- the above-mentioned compound of formula IV is the following formula IV-2,
- ring A42 is the same as the definition of ring A4 in the above formula IV;
- the B42 ring is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are -CF 3 ; further more preferably, the B42 ring is
- R 421 and R 422 are each independently selected from: C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogens, C1-C6 alkane substituted by 1-6 halogens Oxygen, halogen, cyano, amino; or R 421 and R 422 , and the atoms connected to them together form a 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring; preferably, R 421 and R 422 are independently Selected from: C1-C6 alkyl; or R 421 and R 422 , and the atoms connected to them together form a 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring; more preferably, R 421 and R 422 , together with them The connected atoms together form a 5-6 membered heterocyclic ring; most preferably, R 421 and R 422 , together with their connected atom
- the above-mentioned compound of formula IV is the following formula IV-3,
- ring A43 is the same as the definition of ring A4 in the above formula IV;
- Ring B43 is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are -CF 3 ; further more preferably, the B43 ring is R 431 and R 432 are each independently selected from: hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogens, C1- C6 alkoxy, halogen, cyano, amino; or R 431 and R 432 , and the atoms connected to them together form a 5-6 membered heterocyclic ring or a 5-6 membered heteroaromatic ring; preferably, R 431 and R 432 are each independently selected from: hydrogen, C1-C6
- the A5 ring is selected from: and said Optionally substituted by Rm, or optionally substituted by Ry and Rm; wherein, Ry is selected from methyl, -CHF 2 , -CF 3 , CD 3 , -CH 2 CH 3 , -CH 2 CHF 2 , -CH 2 CF 3 , Rm is an oxo group; preferably, the A5 ring and its optional substituents as a whole are selected from: Preferably, ring A5 and its optional substituents as a whole are selected from: Most preferably, ring A5 and its optional substituents, taken as a whole, are selected from:
- Ring B5 is selected from: It is optionally substituted by 1 substituent selected from: C1-C6 alkyl, C1-C6 alkoxy, 1-6 halogen substituted C1-C6 alkyl, halogen; preferably, the The substituents are selected from: C1-C6 alkyl substituted by 1-6 halogens; more preferably, the substituents are -CF 3 ; further more preferably, the B5 ring is R is selected from: hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkoxy substituted by 1-6 halogen, halogen , cyano, amino; preferably, R 5 is selected from C1-C6 alkyl; more preferably, R 5 is -CH 3 .
- R 6' is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxyl, C1-C6 alkyl substituted by 1-6 halogen, C1-C6 alkyl substituted by 1-6 deuterium , C1-C6 alkyl substituted by C3-C6 cycloalkyl, C1-C6 alkyl substituted by C6-C10 aryl, substituted by Substituted C1-C6 alkyl; preferably, R 6' is selected from C1-C6 alkyl, C1-C6 alkyl substituted by hydroxy, C1-C6 alkyl substituted by 1-3 halogens, C1-C6 alkyl substituted by 1-3 C1-C6 alkyl substituted by deuterium, C1-C6 alkyl substituted by cyclopropyl, C1-C6 substituted by phenyl alkyl, More preferably, R 6' is selected from methyl, -C6
- the definition of the B6 ring is the same as the definition of the Bo ring in the above-mentioned formula O; or, the definition of the B6 ring is the same as the definition of the B11 ring in the above-mentioned formula I-1; or, the definition of the B6 ring is the same as that of the B12 ring in the above-mentioned formula I-2
- the definition is the same; or, the definition of the B6 ring is the same as the definition of the B13 ring in the above formula I-3; or, the definition of the B6 ring is the same as the definition of the B14 ring in the above formula I-4; or, the definition of the B6 ring is the same as the above formula
- the definition of the B4 ring in sub-IV is the same;
- the definition of the C6 ring is the same as the definition of the Co ring in the above formula O; or, the definition of the C6 ring is the same as the definition of the C4 ring in the above formula IV;
- R6 is the same as the definition of Ro in the above formula O; or, the definition of R6 is the same as the definition of R11 in the above formula I-1; or, the definition of R6 is the same as the definition of R12 in the above formula I-2 Or, the definition of R6 is the same as the definition of R13 in the above formula I-3; or, the definition of R6 is the same as the definition of R14 in the above formula I-4; or, the definition of R6 is the same as that of the above formula
- the definition of R4 in IV is the same.
- the above-mentioned compound of formula O is the following formula Ox:
- the Aox ring is selected from:
- the Aox ring is Y is selected from CH, N;
- the definition of Rx is the same as the definition of R 121 in the above formula I-2-1; or, the definition of Rx is the same as the definition of R 132 in the above formula I-3-2; preferably, Rx is located at The position on the ring is selected from: 2-position mono-substitution, 3-position mono-substitution, or 2-, 3-position double substitution.
- the above-mentioned compound is selected from the following:
- the present application relates to the preparation of the above-mentioned compounds, or tautomers of the compounds, stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereomers thereof, or tautomers thereof
- a method for a racemate, a prodrug thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, a hydrate thereof, an ester thereof, an isotope thereof, or a metabolite thereof comprising:
- Co ring is the same as the definition of Co ring in the above formula O
- Ro is the same as the definition of Ro in the above formula O
- X is selected from halogen, preferably -F, -Cl.
- step a 1) carry out nucleophilic substitution under basic conditions (such as cesium carbonate, sodium tert-butoxide, sodium hydrogen, potassium tert-butoxide, etc.); 2) Buchwald can also be used Coupling (such as Pd2(dba)3 or Pd G3, Pd G2 and other palladium catalysts, BINAP, Xantphos as phosphorus ligand, Cs2CO3, or sodium tert-butoxide as basic) conditions for the reaction.
- basic conditions such as cesium carbonate, sodium tert-butoxide, sodium hydrogen, potassium tert-butoxide, etc.
- Buchwald can also be used Coupling (such as Pd2(dba)3 or Pd G3, Pd G2 and other palladium catalysts, BINAP, Xantphos as phosphorus ligand, Cs2CO3, or sodium tert-butoxide as basic) conditions for the reaction.
- the solvent in step a is N,N-dimethylformamide or dimethyl sulfoxide, 1,4-dioxane, toluene and the like.
- step b is in carried out in the presence of molecular sieves.
- the solvent of step b is methanol. In some embodiments of the present application, the solvent in step c is tetrahydrofuran.
- the present application relates to the preparation of the aforementioned compounds, or tautomers of said compounds, stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereomers thereof isomers, racemates thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, hydrates thereof, esters thereof, isotopes thereof, or metabolites thereof, comprising :
- R 1' is the same as the definition of Ro in the above formula O;
- R 2' is selected from -CF 3 , -Cl, -SF 5 , -CH 3 , -F, -OCH 3 , -OCF 3 ;
- R 3' is selected from H, -CH 3 ; R 4' is selected from -CN, LG 1 is a leaving group, preferably halogen, more preferably -F, -Cl; A 1 , A 2 , A 3 , A 4 are each independently selected from N, CH.
- step m can be designed and synthesized in three different ways.
- Scheme (1) under basic conditions such as cesium carbonate, sodium tert-butoxide, sodium hydrogen, potassium tert-butoxide, etc., use DMF or MeCN as a solvent, and under the condition of heating reaction temperature, the substituted indole will carry out affinity to the C ring Nuclear substitution, introducing a substituted indole ring structure;
- Scheme (2) can be coupled with Buchwald, such as Pd 2 (dba) 3 or Pd G 3 , Pd G 2 , Pd G 4 and other palladium catalysts, in the BINAP phosphorus ligand, In the presence of phosphorus ligands such as Xantphos, use Cs 2 CO 3 , or sodium tert-butoxide as a base, use toluene or 1,4-dioxane as a solvent, and heat to the reaction temperature to carry out the coupling reaction.
- phosphorus ligands such as X
- Scheme (3) can use the ullmann reaction, under CuI catalyzed conditions, L-poline, or trans-N, N'-dimethyl-1,2-cyclohexanediamine, etc. as ligands, with potassium phosphate Alkali, toluene as solvent, heating to a certain temperature for coupling reaction indole substituted indole ring.
- step n can use hydroxylamine hydrochloride, under the conditions of organic bases such as N,N-diethylisopropylamine, triethylamine, etc., methanol is used as a solvent, adding The bar with molecular sieves is heated to 80 degrees, reacted for a certain period of time to obtain the addition of hydroxylamine to the cyano functional group to obtain an amidine structure, and then under the condition of dicarbonylimidazole reagent, DBU is used as an organic base, THF is used as a solvent, and the reaction is detected by TLC. This completes the formation of dioxazolones.
- This structure can be further subjected to an electrophilic substitution reaction by an electrophilic alkyl halide structure to introduce an alkyl side chain, for example
- the present application relates to a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereomer isomers, racemates thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, hydrates thereof, esters thereof, isotopes thereof, or metabolites thereof; optionally, Also contains pharmaceutically acceptable excipients.
- the present application relates to a method for treating cancer in a patient, comprising administering the above-mentioned compound, or the compound to the patient tautomers, stereoisomers, geometric isomers, enantiomers, diastereomers, racemates, prodrugs, pharmaceutically acceptable A salt, a pharmaceutically acceptable solvate thereof, a hydrate thereof, an ester thereof, an isotope thereof, or a metabolite thereof; or the above pharmaceutical composition.
- the cancer is associated with TEAD overexpression.
- the cancer is associated with increased TEAD activity.
- the present application relates to a method for inhibiting cancer progression in a patient, which comprises administering to the patient the above-mentioned compound, or a tautomer of the compound, a stereoisomer thereof, a geometric isomer thereof, Its enantiomers, its diastereoisomers, its racemates, its prodrugs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its hydrates, its esters, its Isotopes, or their metabolites; or the aforementioned pharmaceutical compositions.
- the cancer is associated with TEAD overexpression.
- the cancer is associated with increased TEAD activity.
- the present application relates to a method of treating a patient suffering from a disease or condition associated with increased expression of TEAD, comprising administering to the patient the above-mentioned compound, or a tautomer of the compound, Stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereomers thereof, racemates thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts thereof A solvate, a hydrate thereof, an ester thereof, an isotope thereof, or a metabolite thereof; or the above pharmaceutical composition.
- the present application relates to a method of treating a patient suffering from a disease or condition associated with increased TEAD activity, comprising administering to the patient the above compound, or a tautomer of the compound, its Stereoisomers, geometric isomers thereof, enantiomers thereof, diastereomers thereof, racemates thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvents thereof compounds, hydrates thereof, esters thereof, isotopes thereof, or metabolites thereof; or the aforementioned pharmaceutical compositions.
- the present application relates to a method of treating a disease or disorder, wherein inhibition of TEAD activity will be beneficial to the disease or disorder, comprising administering the above-mentioned compound, or a tautomer of the compound to the patient , its stereoisomers, its geometric isomers, its enantiomers, its diastereomers, its racemates, its prodrugs, its pharmaceutically acceptable salts, its pharmaceutically acceptable
- the present application relates to a method of treating a disease or disorder for which inhibition of the Hippo pathway will be beneficial for the disease or disorder, comprising administering the above compound, or a tautomer of the compound to the patient , its stereoisomers, its geometric isomers, its enantiomers, its diastereoisomers, its racemates, its prodrugs, its pharmaceutically acceptable salts, its pharmaceutically acceptable
- the disease or disorder is a cell proliferative disorder.
- the cell proliferative disease is cancer.
- the cancer is one in which YAP is localized in the nucleus of the cancer.
- the TEAD overexpression or TEAD activity increase is TEAD1 overexpression or TEAD1 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD2 overexpression or TEAD2 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD3 overexpression or TEAD3 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD4 overexpression or TEAD4 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD1 overexpression or TEAD1 activity increase; TEAD2 overexpression or TEAD2 activity increase; TEAD3 overexpression or TEAD3 activity increase; or TEAD4 overexpression or TEAD4 activity increase; or any combination thereof.
- the present application relates to the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereoisomer, Its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition in the preparation of therapeutic Use in medicine for cancer.
- the cancer is associated with TEAD overexpression.
- the cancer is associated with increased TEAD activity.
- the present application relates to the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereoisomer, Its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above-mentioned pharmaceutical composition Use in a medicament to inhibit the progression of cancer.
- the cancer is associated with TEAD overexpression.
- the cancer is associated with increased TEAD activity.
- the present application relates to one of the aforementioned compounds, or tautomers of said compounds, stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereoisomers thereof body, its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition
- Use in the preparation of a medicament for treating diseases or conditions associated with increased expression of TEAD Use in the preparation of a medicament for treating diseases or conditions associated with increased expression of TEAD.
- the present application relates to a compound as described above, or a tautomer of said compound, a stereoisomer thereof, a Geometric isomers, their enantiomers, their diastereoisomers, their racemates, their prodrugs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and their hydrates , its ester, its isotope, or its metabolite; or the use of the above pharmaceutical composition in the preparation of a medicament for the treatment of diseases or disorders associated with increased TEAD activity.
- the present application relates to one of the aforementioned compounds, or tautomers of said compounds, stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereoisomers thereof body, its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition
- the present application relates to one of the aforementioned compounds, or tautomers of said compounds, stereoisomers thereof, geometric isomers thereof, enantiomers thereof, diastereoisomers thereof body, its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition in Use in the manufacture of a medicament for treating a disease or disorder associated with the Hippo pathway; wherein inhibition of the Hippo pathway would benefit the disease or disorder.
- the disease or disorder is a cell proliferative disorder.
- the cell proliferative disease is cancer.
- the cancer is one in which YAP is localized in the nucleus of the cancer.
- the TEAD overexpression or TEAD activity increase is TEAD1 overexpression or TEAD1 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD2 overexpression or TEAD2 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD3 overexpression or TEAD3 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD4 overexpression or TEAD4 activity increase.
- the TEAD overexpression or TEAD activity increase is TEAD1 overexpression or TEAD1 activity increase; TEAD2 overexpression or TEAD2 activity increase; TEAD3 overexpression or TEAD3 activity increase; or TEAD4 overexpression or TEAD4 activity increase; or any combination thereof.
- the present application relates to the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereoisomer, Its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite, or the above pharmaceutical composition has Use in a medicament for the activity of binding to TEAD and blocking the interaction between YAP/TEAD.
- the present application relates to a method for treating a disease or disorder in a patient, which comprises administering the above-mentioned compound, or a tautomer, a stereoisomer, or a geometric isomer of the compound to the patient , its enantiomers, its diastereoisomers, its racemates, its prodrugs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its hydrates, its esters, Its isotope, or its metabolite; or the above-mentioned pharmaceutical composition; said disease or disease is related to the protein that TEAD interacts with.
- the disease or disorder associated with the TEAD-interacting protein includes, but is not limited to, cancer, metabolic disease, inflammatory disease, or neurodegenerative disease.
- the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, liver cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer , mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, brain cancer, upper aerodigestive tract cancer, colorectal cancer, urinary tract cancer or colon cancer; preferably, the Said cancer is selected from brain cancer, esophageal cancer, renal cancer, mesothelioma, liver cancer, head and neck cancer, lung cancer, gastric cancer, breast cancer or prostate cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma , mixed adenosquamous carcinoma, undifferentiated carcinoma; further preferably, the brain cancer includes but not limited to glioma; head and neck
- the present application relates to the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereoisomer, Its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition in the preparation of therapeutic Use in medicine for a disease or disorder; said disease or disorder is associated with a TEAD-interacting protein.
- the disease or disorder associated with the TEAD-interacting protein includes, but is not limited to, cancer, metabolic disease, inflammatory disease, or neurodegenerative disease.
- the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, liver cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer , mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, brain cancer, upper aerodigestive tract cancer, colorectal cancer, urinary tract cancer or colon cancer; preferably, the Said cancer is selected from brain cancer, esophageal cancer, renal cancer, mesothelioma, liver cancer, head and neck cancer, lung cancer, gastric cancer, breast cancer or prostate cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma , mixed adenosquamous carcinoma, undifferentiated carcinoma; further preferably, the brain cancer includes but not limited to glioma; head and neck
- the present application relates to the above-mentioned compound, or a tautomer of the compound, its stereoisomer, its geometric isomer, its enantiomer, its diastereoisomer , its racemate, its prodrug, its pharmaceutically acceptable salt, its pharmaceutically acceptable solvate, its hydrate, its ester, its isotope, or its metabolite; or the above pharmaceutical composition in Use in the treatment of a disease or disorder; said disease or disorder is associated with a TEAD-interacting protein.
- the disease or disorder associated with the TEAD-interacting protein includes, but is not limited to, cancer, metabolic disease, inflammatory disease, or neurodegenerative disease.
- the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, liver cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer , mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, brain cancer, upper aerodigestive tract cancer, colorectal cancer, urinary tract cancer or colon cancer; preferably, the Said cancer is selected from brain cancer, esophageal cancer, renal cancer, mesothelioma, liver cancer, head and neck cancer, lung cancer, gastric cancer, breast cancer or prostate cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma , mixed adenosquamous carcinoma, undifferentiated carcinoma; further preferably, the brain cancer includes but not limited to glioma; head and neck
- C1-C6 alkyl specifically refers to independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl.
- alkyl is meant to include both branched and straight chain saturated aliphatic hydrocarbon groups having the indicated number of carbon atoms.
- C1-C6 alkyl refers to C1, C2, C3, C4, C5 and C6.
- C1-C6 alkyl means an alkyl group having 1 to 6 carbon atoms, preferably “C1-C4 alkyl", more preferably "C1-C3 alkyl”.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), pentyl (e.g., n- Pentyl, isopentyl, neopentyl) etc.
- alkoxy refers to an oxygen atom substituted with an alkyl group as defined herein.
- C1-C6 alkoxy includes groups -O-C1-C6 alkyl, such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy , tert-butoxy, pentyloxy, 2-pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, 2-hexyloxy, 3-hexyloxy, etc.
- cycloalkyl refers to a cyclized alkyl group, including monocyclic, bicyclic or polycyclic ring systems, which does not contain unsaturated bonds such as double bonds, and does not contain any heteroatoms, such as C3-C8 cycloalkyl, C3- C7 cycloalkyl or C3-C6 cycloalkyl.
- C3-C6 cycloalkyl refers to include C3, C4, C5 and C6 cycloalkyl.
- "3-6 membered cycloalkyl” and “C3-C6 cycloalkyl” can be used interchangeably. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- Ra, Rb and the carbon atoms connected to them together form azetidine
- azetidine is optionally substituted by hydroxyl, for example, can be Other similar definitions can be understood with reference to the foregoing.
- the wavy line in the aforementioned structure The two sites shown represent the sites where the ring formed by the two Ros and the atoms respectively attached to them is fused with the Co ring.
- the structure formed after the two rings are fused can be, for example,
- the structure formed after the fusion of two rings can be, for example,
- the structure formed after the fusion of two rings can be, for example,
- the structure formed after the fusion of two rings can be, for example, for another example, if the ring formed by two Ro and the atoms connected to them is And the Co ring is Then the structure formed after the fusion of two rings can be, for example, for another example, if the ring formed by two Ro and the atoms connected to them is And the Co ring is Then the structure formed after the fusion of two rings can be, for example, For another example, if the ring formed by two Ro and the atoms connected to them is And the Co ring is Then the structure formed after the fusion of two rings can be, for example
- C1-C6 alkyl substituted by hydroxy means that one hydrogen atom in the aforementioned C1-C6 alkyl is replaced by hydroxy, for example Wherein, the definition of alkyl is as described above.
- C1-C6 alkyl substituted by C6-C10 aryl means that one hydrogen atom in the aforementioned C1-C6 alkyl is replaced by C6-C10 aryl, such as benzyl or
- C1-C6 alkyl substituted by amino means that one hydrogen atom in the aforementioned C1-C6 alkyl is replaced by an amino group, for example Similarly, “C1-C6 alkyl substituted by cyano” It means that one hydrogen atom in the aforementioned C1-C6 alkyl is replaced by a cyano group, for example Similarly, "C1-C6 alkyl substituted by C3-C6 cycloalkyl” means that one hydrogen atom in the aforementioned C
- a partially unsaturated C5-C6 carbocyclic ring and a partially unsaturated 5-6 membered heterocyclic ring are each optionally substituted by 1-6 groups selected from halogen and deuterium
- a partially unsaturated Saturated C5-C6 carbocycle and “partially unsaturated 5-6 membered heterocycle” may be unsubstituted, or may be substituted by 1-6 groups selected from halogen and deuterium, and "partially unsaturated C5-C6
- the substituents of the "carbocycle” and the substituents of the "partially unsaturated 5-6 membered heterocycle” do not affect each other, and may be the same or different.
- substituted means that any one or more hydrogens on the designated atom or group are replaced by a selection of the designated group, provided that the designated atom's normal valence is not exceeded.
- the "heteroatom” in the present invention is N, O or S.
- the "halogen” in the present invention is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine or bromine.
- the "(by) 1-6 halogen substituted C1-C6 alkyl" and "(by) 1-6 halogen substituted C1 - C6 alkoxy" in the present invention refer to the said alkyl and a group formed by replacing one or more hydrogen atoms in an alkoxy group with 1-6 halogen atoms, especially fluorine or chlorine atoms.
- fluorination is preferred, eg -CF3 , -CHF2 , -CH2F , -CH2CH2F , -CH2CHF2 , -CH2CF3 , -OCF3 , -OCHF2 , -OCH 2 F, -OCH 2 CH 2 F, -OCH 2 CHF 2 or -OCH 2 CF 3 .
- C1-C6 alkyl substituted by 1-6 deuterium refers to a group formed after one or more hydrogen atoms in the alkyl group are replaced by 1-6 deuterium atoms, for example -CD3 .
- alkenyl refers to a group formed by one or more double bonds in the above-mentioned “alkyl”, preferably “C2-C6 alkenyl”. Preferred examples are
- heteroaryl refers to substituted and unsubstituted aromatic 5-membered or 6-membered monocyclic groups having at least one heteroatom (O, N or S) in at least one ring, 8- Yuan, 9-membered or 10-membered bicyclic groups and 11-membered to 14-membered tricyclic groups, the heteroatom-containing ring optionally also has 1, 2 or 3 members selected from O, N or S of heteroatoms.
- the heteroaryl is preferably a 5-membered or 6-membered monocyclic group (ie "5-6 membered heteroaryl").
- a heteroaryl group can be attached at any available nitrogen or carbon atom of either ring.
- heteroaryl group is limited by the number of carbon atoms, such as "C1-C5 heteroaryl", it means that the heteroaryl group contains carbon atoms of the limited number of carbon atoms, and in addition to carbon atoms also contains 1-5 heteroatoms; for example, "C1-C5 heteroaryl” means that the heteroaryl group contains 1-5 carbon atoms, and contains 1-5 heteroatoms in addition to carbon atoms, such as pyrrole Base, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl , pyridazinyl, triazinyl, triazolyl, etc.
- Exemplary 5-6 membered heteroaryl groups include, but are not limited to: pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl, thiophene Base, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl, etc.
- heterocycle refers to substituted and unsubstituted 3-membered to 7-membered monocyclic groups, 7-membered to 11-membered Membered bicyclic groups and 10- to 15-membered tricyclic groups, which may contain one or more double bonds, but do not constitute aromatic rings; wherein at least one ring has at least one heteroatom (O, S or N) .
- the heterocyclic group is preferably a 5- to 6-membered monocyclic group (ie, "5-6-membered heterocyclic group”).
- a heterocyclic group can be attached at any available nitrogen or carbon atom.
- heterocyclic group does not contain one or more double bonds, it is called “saturated heterocyclic group”. Similarly, if the heterocyclic group contains one or more double bonds and does not constitute an aromatic ring, it is called “unsaturated heterocyclic group”.
- the heterocyclic group is limited by carbon atoms, such as “C3-C5 heterocyclic group", it means that the heterocyclic group contains carbon atoms with the limited number of carbon atoms, and in addition to carbon atoms, it also contains 1 -2 heteroatoms; for example, "C3-C5 heterocyclic group” means that the heterocyclic group contains 3-5 carbon atoms, and contains 1-2 heteroatoms in addition to carbon atoms, for example
- Exemplary 5-6 membered heterocyclyl groups include azetidinyl, oxetanyl, pyrrolidinyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, tetrahydrofuranyl, piperidine Pyridyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepine, 1-pyridonyl, 4 -piperidinonyl, tetrahydropyranyl, morpholinyl, 1,3-dioxolyl, etc.
- a 5-membered unsaturated heterocycle be oxo or be oxo Substituted by the substituent, the substituted structural formula is Similarly, if thiomorpholino When it is substituted by two oxo groups, and the substitution site is S, the substituted structural formula
- Other similar definitions can be understood with reference to the foregoing.
- a direct bond means that the groups on both sides are directly connected, for example, the formula O In , if L 0 is a direct bond, the structural formula of formula O will become Other similar definitions can be understood with reference to the foregoing.
- the dotted line bond------ refers to the existence or non-existence of the bond.
- Formula O Among them, if Ro is 0, it means that Ro does not exist, that is, the structural formula of formula O becomes If Ro is 1, the structural formula of formula O becomes If Ro is 2, the structural formula of formula O becomes In addition, the two definitions of Ro are independent of each other, and may be the same or different. Other similar structural formulas or definitions can be understood with reference to the foregoing.
- treatment generally refers to obtaining desired pharmacological and/or physiological effects.
- the effect may be prophylactic in terms of complete or partial prevention of the disease or its symptoms; and/or therapeutic in terms of partial or complete stabilization or cure of the disease and/or side effects due to the disease.
- Treatment encompasses any treatment of a disease in a patient, including: (a) prophylaxis of a disease or condition in a patient susceptible to the disease or condition but not yet diagnosed; (b) suppressing the symptoms of the disease, ie arresting its development; or (c) alleviating the symptoms of the disease, ie causing regression of the disease or symptoms.
- a vertebrate refers to a vertebrate.
- a vertebrate is a mammal.
- Mammals include, but are not limited to, livestock (such as cattle), pets (such as cats, dogs, and horses), primates, mice, and rats.
- a mammal is a human.
- an effective amount refers to the amount effective to achieve the desired therapeutic or preventive effect at the necessary dose and time.
- a “therapeutically effective amount” of a molecule can vary depending on factors such as the disease state, age, sex and weight of the individual and the ability of the substance/molecule to elicit a desired response in the individual.
- a therapeutically effective amount also encompasses an amount in which any toxic or detrimental consequences are outweighed by the therapeutically beneficial effects of the substance/molecule.
- a “prophylactically effective amount” refers to an amount effective at dosages and for periods of time necessary to achieve the desired prophylactic effect.
- the prophylactically effective amount will be lower than the therapeutically effective amount because the prophylactic dose is administered to the subject before the onset of the disease or at an early stage of the disease.
- the therapeutically effective amount of the drug reduces the number of cancer cells; reduces tumor volume; inhibits (i.e. slows down to some extent, preferably stops) the infiltration of cancer cells into surrounding organs; inhibits (i.e. slows down to some extent, preferably stops) ) tumor metastasis; inhibition of tumor growth to a certain extent; and/or alleviation of one or more symptoms associated with cancer to a certain extent.
- auxiliary materials include but are not limited to: ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphate , glycerin, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal oxidation Silicon, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances, macrogol, sodium carboxymethylcellulose, polyacrylates, beeswax, lanolin, etc.
- ion exchangers aluminum oxide, aluminum stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphate , glycerin, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts
- the pharmaceutical composition of the present invention can be prepared in various forms according to different administration routes.
- the pharmaceutical composition can be administered in any of the following ways: oral, inhalation spray, rectal, nasal, buccal, vaginal, topical, parenteral, such as subcutaneous, intravenous, intramuscular, peritoneal Intrathecal, intraventricular, intrasternal and intracranial injection or infusion, or with the aid of an explanted reservoir.
- oral, intraperitoneal or intravenous administration is preferred.
- prodrug refers to a derivative that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide a compound of the invention. Prodrugs undergo this reaction only under biological conditions to become active compounds, or they are active in their unreacted form. Prodrugs can generally be prepared using well-known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5th ed.).
- Tautomers in the compounds described herein refer to two isomers containing heteroatoms (such as nitrogen, oxygen or sulfur atoms) whose structures differ only in the migration of protons and corresponding double bonds , and these two isomers coexist in an equilibrium system, and they are transformed into each other at a very high rate.
- Typical examples, such as the group in this paper Can be transformed by tautomerism into Furthermore, both coexist. Therefore, if the structural formula of the compound described herein is Those skilled in the art can understand that its representation structure and structure simultaneously exist. If there are similar groups in other compounds, it should be understood with reference to the aforementioned content.
- geometric isomers the isomers caused by double bonds or single bonds of ring carbon atoms that cannot rotate freely are called geometric isomers, also known as cis-trans isomers.
- enantiomer stereoisomers that are real and mirror images of each other but not superimposable are called enantiomers.
- diastereoisomers refer to stereoisomers whose molecules have two or more chiral centers and which are not mirror images.
- racemate refers to an equimolar mixture of an optically active chiral molecule and its enantiomer.
- the meso form refers to a molecule with two or more asymmetric centers, but there are other symmetry factors, such as symmetry planes, so that the entire molecule does not have optical activity and no enantiomers exist, usually in the form of meso or i said.
- hydrate refers to a compound that exists in combination with water molecules.
- the combination may include water in stoichiometric amounts, such as the monohydrate or dihydrate, or may include any amount of water.
- esters refers to an ester of -COOH present in the compounds provided by the invention with a suitable alcohol, or an -OH present in the compounds provided by the present invention with a suitable acid (e.g., carboxylic acid or oxygen-containing inorganic acids) to form esters.
- suitable ester groups include, but are not limited to, formate, acetate, propionate, butyrate, acrylate, ethylsuccinate, stearate, or palmitate. In the presence of acid or base, esters can be hydrolyzed to produce corresponding acids or alcohols.
- isotopes Different atoms of the same element with the same number of protons but different numbers of neutrons are called isotopes.
- isotope of a compound refers to the structure formed after one or more atoms in the compound provided by the present invention are replaced by its isotope.
- the "metabolite” mentioned herein refers to the intermediate metabolite or the final metabolite of the compound provided by the present invention under certain metabolic conditions.
- the "pharmaceutically acceptable salt” in the present invention refers to the acid addition salt prepared by reacting the compound of the present invention with a pharmaceutically acceptable acid, or the salt formed by the reaction of a compound with an acidic group and a basic compound .
- the acid is preferably selected from inorganic acids (such as hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid, etc.), and organic acids (such as oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, lysine , histidine, citric acid or benzoic acid, etc.); said basic compound is preferably selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate or potassium bicarbonate and the like.
- the above pharmaceutically acceptable salts are easy to separate and can be purified by conventional separation methods, such as solvent extraction, dilution, recrystallization, column chromatography and preparative thin-layer chromatography.
- Solvate is a compound that exists in combination with certain solvent molecules.
- the combination may include stoichiometric amounts of certain solvents, such as monohydrate or dihydrate, or may include any amount of water; as another example, methanol or ethanol may form “alcoholates,” which may also be stoichiometric or non-stoichiometric.
- solvate refers to a solid form, ie, a compound in solution in a solvent, although it may be solvated, it is not a solvate as the term is used herein.
- the compounds described in the present invention can optionally be used in combination with one or more other active ingredients, and their respective dosages and ratios can be adjusted by those skilled in the art according to specific diseases, specific conditions of patients, and clinical needs.
- Step 1 Add 5-(trifluoromethyl)-1H-indole (1.53g, 8.26mmol) to 3-fluoro-2-benzonitrile (1.0g, 8.26mmol), cesium carbonate (5.38g, 16.52 mmol) and N,N-dimethylformamide (8 mL). The reaction mixture was stirred at 80°C for 3 hours, diluted with water (15 mL), and extracted with ethyl acetate (45 mL).
- Step 1 To a solution of 3-chloropyrazine-2-carbonitrile (250 mg, 1.79 mmol) and sodium tert-butoxide (172.17 mg, 1.79 mmol) in N,N-dimethylformamide (8 mL) was added 5- (Trifluoromethyl)-1H-indole (331.71 mg, 1.79 mmol). After the reaction mixture was stirred at 120° C. for 3 hours, it was diluted with water (15 mL), and then extracted with ethyl acetate (45 mL).
- Step 2 To a mixture of compound 2-1 (100 mg, 3.05 mmol), triethylamine (0.97 mL, 7.00 mmol) and molecular sieves (100 mg), and methanol (4 mL) was added hydroxylamine hydrochloride (121.61 mg, 1.75 mmol). After stirring the reaction mixture at 80° C. for 2 hours, it was filtered, and the resulting filtrate was concentrated. Water (10 mL) was added to the obtained concentrate, followed by extraction with ethyl acetate (30 mL).
- Step 3 Add CDI (69.40mg, 0.43mmol) to compound 2-2 (110mg, 0.34mmol) in tetrahydrofuran (3mL) at 0°C, stir at room temperature for 0.5 hours, then add DBU (76.66 ⁇ L, 0.51 mmol). The reaction mixture was stirred at room temperature for 1 hour, diluted with water (15 mL), and extracted with ethyl acetate (45 mL).
- Step 4 CDI (0.03 mL, 0.25 mmol) was added to N-hydroxy-5-methyl-3-(5-(trifluoromethyl)-1H-indol-1-yl)pyridine at 0 °C A solution of oxazine-2-carboxamidine (66 mg, 0.20 mmol) in tetrahydrofuran (1 mL) was stirred at 0°C for 0.5 hour, and DBU (0.04 mL, 0.30 mmol) was added at 0°C. The reaction mixture was warmed to room temperature and stirred for 1 hour, diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3).
- Step 1 To a solution of 3,5-dichloropyrazine-2-carbonitrile (1.0 g, 5.75 mmol) in methanol (25 mL) was added sodium methoxide (117.19 mg, 2.17 mmol) at 0°C. The reaction mixture was stirred at room temperature for 12 hours and then concentrated. Water (15 mL) was added to the obtained concentrate, followed by extraction with ethyl acetate (45 mL).
- Step 2 To compound 5-1 (100 mg, 22.99 mmol) and sodium tert-butoxide (56.67 mg, 0.59 mmol) in N,N-dimethylformamide (5 mL) was added 5-(trifluoromethyl) -1H-indole (109.19mg, 0.59mmol). The reaction mixture was stirred at 120°C for 12 hours, diluted with water (10 mL), and extracted with ethyl acetate (30 mL).
- Step 4 Add N,N'-carbonyldiimidazole (11.54 mg, 0.07 mmol) to compound 5-3 (20 mg, 0.06 mmol) in tetrahydrofuran (2 mL) at 0°C, and stir at room temperature for 0.5 hours, 1,8-Diazabicyclo[5.4.0]-7-undecene (12.75 ⁇ L, 0.09 mmol) was added. After stirring the reaction mixture for 1 hour, it was diluted with water (15 mL), and extracted with ethyl acetate (45 mL).
- Step 1 To a solution of 3,6-dichloropyrazine-2-carbonitrile (4.0 g, 22.99 mmol) and sodium tert-butoxide (2.65 g, 27.59 mmol) in N,N-dimethylformamide (45 mL) 5-(Trifluoromethyl)-1H-indole (4.26 g, 22.99 mmol) was added. The reaction mixture was stirred at 120°C for 12 hours, diluted with water (60 mL), and extracted with ethyl acetate (180 mL).
- Step 3 To compound 6-2 (100mg, 0.29mmol), triethylamine (0.40mL, 2.85mmol) and To a solution (4 mL) of molecular sieves (100 mg) in ethanol was added hydroxylamine hydrochloride (99.19 mg, 1.43 mmol). The reaction mixture was stirred and refluxed at 80°C for 3 hours, concentrated, then added with water (15 mL), and extracted with ethyl acetate (45 mL).
- Step 4 Add N,N'-carbonyldiimidazole (155.78mg, 0.96mmol) to compound 6-3 (273mg, crude product, 0.77mmol) in tetrahydrofuran (10mL) at 0°C, and stir the mixture at room temperature for 0.5 After hours, 1,8-diazabicyclo[5.4.0]-7-undecene (172.08 ⁇ L, 1.15 mmol) was added. The reaction mixture was stirred for 1 hour, diluted with water (15 mL), and extracted with ethyl acetate (45 mL).
- Step 1 Trimethylboroxane (0.14mL, 0.50mmol, 3.5M in THF), potassium carbonate (513.95mg, 3.72mmol) and pd(dppf)Cl 2 (45.35mg, 0.06mmol) were added to In a solution of compound 6-1 (400mg, 1.24mmol) in dioxane (4mL) and water (0.5mL). The reaction mixture was warmed up to 100° C. and stirred overnight under nitrogen protection, filtered, and the resulting concentrate was diluted with water (10 mL), and extracted with ethyl acetate (10 mL*3).
- Step 3 At 0°C, CDI (0.03mL, 0.23mmol) was added to a solution of the crude product of compound 7-2 (60mg) in tetrahydrofuran (1mL), stirred at 0°C for 0.5h, then at 0°C DBU (0.04 mL, 0.28 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 1 h, diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3). The combined organic phases were concentrated, and the resulting residue was purified by preparative high-performance liquid chromatography (HPLC) to obtain compound 7 (19.69 mg, 0.05 mmol, yield 29.12%, purity 98.79%).
- HPLC preparative high-performance liquid chromatography
- Step 1 To a solution of compound 2-chloro-4-methoxynicotinonitrile (300 mg, 1.78 mmol) in DMF (6 mL) was added 5-trifluoromethylindole (330 mg, 1.78 mmol) and sodium tert-butoxide ( 171 mg, 1.78 mmol). The reaction mixture was stirred at 120°C for 2 hours, cooled to 25°C, quenched by adding saturated ammonium chloride solution (10 mL) and extracted with EA (50 mL). The combined organic phases were washed with brine (3 times), dried and concentrated.
- Step 2 Add hydroxylamine hydrochloride (440mg, 6.3mmol) successively to compound 8-1 (200mg, 0.63mmol) in methanol (10mL) solution, Molecular sieves (200 mg) and triethylamine (5.0 mL, 37.8 mmol). The reaction mixture was stirred overnight at 75°C, cooled to 25°C and filtered. Sat ammonium chloride solution (15 mL) was added to the filtrate to quench and extracted with EA (100 mL). The combined organic phases were washed with saturated brine (3 times), dried and concentrated.
- Step 3 Add CDI (82.5mg, 0.505mmol) to compound 8-2 (101mg, 0.29mmol) in THF (3mL) at 0°C, warm to room temperature and stir for 30 minutes overnight, then cool to 0 °C, DBU (63 ⁇ L, 0.42 mmol) was added, warmed to room temperature and stirred for 1 hour, then concentrated. To the concentrate was added saturated ammonium chloride solution (2 mL) to quench the reaction, and extracted with EA (20 mL). The combined organic phases were washed with saturated brine (3 times), dried and concentrated.
- Step 1 Disperse tert-butoxycarbonyl sarcosine (143.04mg, 0.76mmol) and HATU (359.33mg, 0.95mmol) in dichloromethane (5mL), stir at room temperature for 3mins, then add compound 9-1 (200mg, 0.63mmol) and N,N-diisopropylethylamine (0.21mL, 1.26mmol). After the reaction mixture was stirred at room temperature for 3 hours, it was quenched by adding saturated sodium bicarbonate (2 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 4 Under stirring at room temperature, cyanogen bromide (49.00mg, 0.46mmol) was added to dissolved compound 9-4 (150mg, 0.31mmol) and N,N-diisopropylethylamine (0.15mL, 0.93mmol ) in tetrahydrofuran (2 mL). After the reaction mixture was stirred at room temperature for 10 minutes, it was quenched with water (1 ml), and extracted with ethyl acetate (30 mL ⁇ 3). The combined organic phases were washed successively with saturated ammonium chloride solution (5 ml) and saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated.
- Step 1 According to the similar synthesis method of step 1 in Example 2, compound 10-1 was prepared by using ethyl 2-chloronicotinate and 5-(trifluoromethyl)-indole as reactants.
- LCMS: m/z 335 [M+H] + .
- Step 2 Compound 10-2 was prepared according to the similar synthesis method of Step 2 in Example 2, using compound 10-1 as a reactant.
- LCMS: m/z 321 [M+H] + .
- Step 1 Compound 11-1 was prepared according to the similar synthesis method of Step 1 in Example 9, using compound 10-2 as a reactant.
- LCMS: m/z 506 [M+H] + .
- Step 2 Compound 11-2 was prepared according to the similar synthesis method of Step 2 in Example 9, using compound 11-1 as a reactant.
- LCMS: m/z 488 [M+H] + .
- Step 3 According to the similar synthesis method of Step 3 in Example 9, Compound 11-3 was prepared using Compound 11-2 as a reactant.
- LCMS: m/z 388 [M+H] + .
- Step 1 Mix 5-trifluoromethylindole (5.00g, 27.01mmol), DMF (20mL), ethyl 2-chloronicotinate (7.52g, 40.51mmol) and Cs 2 CO 3 (17.60g, 17.60mmol ) was purged three times with N 2 , stirred at 120° C. for 3 h, diluted with H 2 O (200 mL), and extracted with EA (50 mL). The combined organic phases were washed with saturated brine (20 mL ⁇ 3), dried over anhydrous Na 2 SO 4 , and concentrated to obtain The residue.
- Step 1 Slowly add LDA/THF (2M, 4.8mL, 4.78mmol) dropwise to a solution of compound 12-3 (2.14g, 8.32mmol) in THF (20mL) under ice bath and nitrogen atmosphere, and stir for 1 hour Then MeI (1.36 g, 9.57 mmol) was added dropwise. The reaction mixture was stirred for an additional 2 h in the ice bath and then quenched with saturated NH4Cl (20 mL) and extracted with EA (50 mL). The combined organic phases were washed with saturated brine (20 mL ⁇ 3), dried over anhydrous Na 2 SO 4 , and concentrated to obtain a residue.
- LDA/THF 2M, 4.8mL, 4.78mmol
- Step 4 Under stirring conditions, T3P/EA (50%, 5.44g, 8.55mmol) was added dropwise to the crude product of compound 12-6 obtained in the above step 3, DMF (15mL), compound 12-2 (0.68g , 2.14mmol) and DIPEA (1.42mL, 8.55mmol) in a mixture. The reaction mixture was stirred at room temperature for 10 min, quenched by adding saturated NaHCO 3 (20 mL), and extracted with EA (50 mL). The combined organic phases were washed with saturated brine (50 mL ⁇ 3), dried over anhydrous Na 2 SO 4 , and concentrated to obtain a residue.
- Step 1 The crude product of compound 14-2 obtained in the above step (1.87g, 5.40mmol) (45.4% by content), 5mL DMF, HATU (2.26g, 5.94mmol) and DIPEA (1.34mL, 8.10mmol) After the mixture was stirred at room temperature for 10 min, compound 14-3 (1.73 g, 5.40 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours, concentrated, added saturated NaHCO 3 (aq) (50 mL), extracted with EA (30 mL). The combined organic phases were concentrated to give a residue.
- Step 3 Under the condition of 0 °C and N 2 atmosphere, compound 16-3 (200mg, 0.63mmol) was slowly added to the dissolved monoethyl oxalyl chloride (0.07mL, 0.63mmol) and triethylamine (0.26mL, 1.88 mmol) in dichloromethane (5 mL). Maintaining the N2 atmosphere, the reaction mixture was stirred overnight at room temperature, p-toluenesulfonyl chloride (0.12mL, 0.63mmol) was added, and then the reaction was continued at room temperature for 5 hours, quenched by adding a saturated solution of sodium bicarbonate, and washed with ethyl acetate (50 mL ⁇ 2) extraction.
- Step 4 Tosyl chloride (83mg, 0.44mmol) and triethylamine (0.12mL, 0.87mmol) were sequentially added to compound 16-4 dissolved in dichloromethane (2mL) at room temperature under N2 atmosphere ( 183mg, 0.44mmol) solution. Maintaining the N 2 atmosphere, the reaction mixture was stirred at room temperature for 5 hours, concentrated, added water, and extracted with ethyl acetate (50 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 5 Aqueous ammonia (0.4 mL, 10.39 mmol) was added into methanol (2 mL) dissolved with compound 16-5 (173 mg, 0.43 mmol) in a dry 25 mL sealed tube at room temperature under N 2 atmosphere. After the reaction mixture was quickly sealed, the temperature was slowly raised to 60° C. and stirred for 4 hours, concentrated, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue. The resulting residue was purified by silica gel column chromatography (eluted with ethyl acetate) to obtain compound 16 (136 mg, yield: 84.74%).
- Step 1 A solution of compound 16 (30 mg, 0.08 mmol) dissolved in DMF (2 mL) was purged with N 2 at room temperature and maintained under N 2 atmosphere, cooled to 0° C., and at this temperature, sodium hydride ( 9.67mg, 0.24mmol), and after stirring for 30 minutes, methyl iodide (11.04uL, 0.18mmol) was added. After the reaction mixture was slowly warmed to room temperature, it was stirred for 30 minutes, quenched by adding saturated sodium thiosulfate solution, added water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 Compound 21-1 was prepared according to the similar synthesis method of Step 1 in Example 9, using compound 12-2 as a reactant.
- LCMS: m/z 421 [M+H] + .
- Step 2 Compound 21 (10 mg, 0.024 mmol, yield: 35.33%, purity: 97.10%) was prepared according to the similar synthesis method of step 4 in Example 9, using compound 21-1 as a reactant.
- MS (ESI): m/z 433 [M+H] + .
- Step 1 5-Trifluoromethylindole (212 mg, 1.14 mmol) and Cs 2 CO 3 (745 mg, 2.28 mmol) were added to 1-bromo-2-fluorobenzene (200 mg, 1.14 mmol) in DMSO (5 mL) in solution.
- the reaction mixture was stirred under microwave conditions at 130° C. for 2 h, cooled to room temperature, diluted with H 2 O and extracted with EA. The combined organic phases were dried and concentrated to give a residue.
- the obtained residue was purified by silica gel column chromatography to obtain compound 24-1 (350 mg, 1.04 mmol).
- MS (ESI): m/z 340 [M+H] + .
- Step 2 Add compound 2-methyl-5-(tributyltin)-2H tetrazole (442 mg, 1.18 mmol), Pd( PPh 3 ) 4 (68 mg, 0.06 mmol) and Cul (12 mg, 0.06 mmol). The reaction mixture was stirred overnight at 120 °C, cooled to room temperature, diluted with potassium fluoride solution (2M) and extracted with EA. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a residue. The resulting residue was purified by silica gel column chromatography to obtain compound 24 (68 mg, 0.20 mmol, yield: 33.9%).
- Step 1 To compound 26-1 (200mg, 0.59mmol), potassium carbonate (162.52mg, 1.18mmol) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (48.02mg, 0.06mmol) to a mixture of dioxane (2.5mL) and water (0.5mL) was added 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxane Pentaboran-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylic acid tert-butyl ester (443.69 mg, 1.18 mmol). The reaction mixture was purged with nitrogen and maintained under nitrogen atmosphere.
- Step 1 To a solution of compound 26-1 (150 mg, 0.44 mmol) in 1,4-dioxane/water (4 mL/0.8 mL) was sequentially added compound 29-1 (203 mg, 0.66 mmol), Pd(dppf) Cl2 (36mg, 0.044mmol) and sodium carbonate (93mg, 0.8mmol). The reaction mixture was reacted under nitrogen atmosphere at 105°C for 16 hours, quenched by adding saturated ammonium chloride solution (4 mL), and extracted with EA (40 mL). The combined organic phases were washed with saturated brine, dried, and concentrated to obtain a residue.
- Step 1 To a solution of compound 26-1 (150 mg, 0.44 mmol) in 1,4-dioxane/water (4 mL/0.8 mL) was sequentially added compound 31-1 (166 mg, 0.66 mmol), Pd(dppf) Cl2 (36mg, 0.044mmol) and sodium carbonate (93mg, 0.8mmol). The reaction mixture was stirred under N 2 atmosphere at 105 °C for 16 h, cooled to room temperature, quenched by adding saturated ammonium chloride solution (4 mL), and extracted with EA (40 mL). The combined organic phases were washed with saturated brine, dried and concentrated to obtain a residue.
- Step 1 Mix DMSO (10 mL), 5-trifluoromethylindole (1.50 g, 8.10 mmol), 3-fluorobenzocyanide (0.98 g, 8.10 mmol) and Cs 2 CO 3 (5.28 g, 16.20 mmol) The mixture was purged with N 2 and maintained under N 2 atmosphere, the reaction mixture was stirred at 90° C. for 4 h, diluted with H 2 O (30 mL), and extracted with EA (50 mL). The combined organic phases were washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 2 Add MeOH (50mL), compound 39-1 (1.00g, 3.49mmol), NH 2 OH ⁇ HCl (2.43g, 34.93mmol), TEA (29mL) and Molecular sieves (1.00 g).
- the reaction mixture was purged with N2 and maintained at N2 atmosphere, stirred at 80 °C After stirring for 4 hours, the filtrate was concentrated after suction filtration.
- H2O (20 mL), and extracted with EA (30 mL). The combined organic phases were dried over anhydrous Na 2 SO 4 and concentrated to obtain a crude product (1.23 g) of compound 39-2 (MS (ESI): m/z 320 [M+H] + ).
- Step 3 Add CDI (380.9 mg, 2.35 mmol) to the crude product of compound 39-2 (500.0 mg) in THF (10 mL) under ice-bath conditions, stir at room temperature for 30 minutes, and again in the ice-bath Under conditions, DBU (357.6 mg, 2.35 mmol) was added dropwise. The reaction mixture was stirred under ice bath for 1 h, H 2 O (20 mL) was added, and extracted with EA (30 mL). The combined organic phases were concentrated to obtain a residue, and the obtained residue was purified by preparative high-performance liquid chromatography (HPLC) to obtain compound 39 (360 mg, 1.04 mmol, yield: 66.58%).
- HPLC preparative high-performance liquid chromatography
- Step 2 Add hydroxylamine hydrochloride (490 mg, 7.0 mmol) successively to compound 40-1 (200 mg, 0.70 mmol) in methanol (10 mL), Molecular sieves (200 mg) and triethylamine (5.4 mL, 47 mmol). The reaction mixture was stirred at 75°C for 3 hours, cooled to 25°C, and filtered. To the resulting filtrate was added saturated ammonium chloride solution (15 mL) to quench the reaction, and extracted with EA (100 mL). The combined organic phases were washed with saturated brine (3 times), dried and concentrated to obtain a residue.
- Step 3 Add CDI (57mg, 0.35mmol) to a solution of compound 40-2 (90mg, 0.28mmol) in THF (2mL) at 0°C, warm to room temperature, stir at room temperature for 30 minutes and then cool to 0°C , DBU (63 ⁇ L, 0.42 mmol) was added at 0° C., warmed to room temperature again, stirred at room temperature for 1 hour and then concentrated. Saturated ammonium chloride solution (2 mL) was added to the concentrate to quench the reaction, and extracted with EA (20 mL). The combined organic phases were washed with saturated brine (3 times), dried and concentrated to obtain a residue.
- Step 1 Dissolve 2-fluorobenzonitrile (0.27mL, 2.48mmol), 5-trifluoromethoxyindole (498.27mg, 2.48mmol) and cesium carbonate (1614.17mg, 4.95mmol) in succession at room temperature in DMSO (10 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 120° C., stirred for 1 hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 2 At room temperature, successively add hydroxylamine hydrochloride (1551.83mg, 22.33mmol), Molecular sieves (675 mg, 2.23 mmol) and TEA (18.57 mL, 133.99 mmol) were added to a solution of compound 41-1 (675 mg, 2.23 mmol) in methanol (30 mL).
- the reaction mixture was used N 2 purged and maintained N 2 atmosphere, slowly warmed up to 75 °C and stirred overnight, quenched by adding saturated ammonium chloride solution, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 3 N,N'-carbonyldiimidazole (199.49 mg, 1.23 mmol) was added to a solution of compound 41-2 (330 mg, 0.98 mmol) in THF (5 mL) at 0°C.
- the reaction mixture was warmed up to room temperature, stirred at room temperature for 30 minutes, cooled to 0°C, added DBU (0.22mL, 1.48mmol), warmed up to room temperature again, stirred at room temperature for 1 hour, quenched with saturated ammonium chloride solution and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 1 Add 5-trifluoromethylindole (359mg, 1.90mmol) and cesium carbonate (1.23g, 3.8mmol) to 3-bromo-4-fluoro-N-toluenesulfonamide (510mg, 1.90mmol) DMSO (14mL) solution.
- the reaction mixture was reacted under microwave conditions (130W, 120°C) for 40min, cooled to 25°C, quenched with saturated ammonium chloride solution, and extracted with EA (100mL). The combined organic phases were washed with saturated brine (3 times), dried and concentrated.
- Step 2 To compound 42-1 (494mg, 1.14mmol) in 1.4-dioxane/water (10mL/2ml) solution, add 1-methyl-4-(4,4,5,5-tetramethyl 1,3,2-Dioxybenzaldehyde-2-yl)-1H imidazole (474mg, 2.28mmol), Pd(dppf)Cl 2 ⁇ CH 2 Cl 2 (114mg, 0.14mmol), sodium carbonate (242mg, 2.28 mmol). The reaction mixture was purged with N2 and maintained under N2 atmosphere, stirred at 80 °C for 7 h, quenched with saturated ammonium chloride solution (10 mL), and extracted with EA (60 mL).
- Step 1 Mix 2-chloro-3-fluoropyridine (0.76mL, 7.60mmol), 5-(trifluoromethyl)indole (1.41g, 7.60mmol) and cesium carbonate (4.95g, 15.21mmol) at room temperature ) was dispersed in N,N-dimethylformamide (12 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed up to 120°C and stirred for 1 hour, then diluted with water and extracted with ethyl acetate (100 mL ⁇ 3).
- Step 2 In a dry 50mL single-necked bottle, dissolve methylamine hydrochloride (6.34g, 93.93mmol) in H 2 O (20mL) at 0°C and add sodium bicarbonate (10.52 g, 125.24mmol) (aq), and finally 3-bromobenzenesulfonyl chloride (4.52mL, 31.31mmol) dissolved in tetrahydrofuran (60mL) was added to the reaction system to replace N 2 . The reaction system was slowly raised to room temperature and stirred for 2 hours.
- Step 3 In a dry 50mL single-necked bottle, compound 47-1 (1.1g, 4.40mmol), pinacol diborate (1.12g, 4.40mmol), potassium acetate (1.08g, 11.00mmol) were sequentially mixed at room temperature ) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.36g, 0.44mmol) were dissolved in dimethyl sulfoxide (13mL) and replaced with nitrogen , the reaction system was slowly warmed up to 80°C and stirred for 6 hours.
- Step 4 At room temperature, compound 47-3 (100mg, 0.34mmol), compound 47-2 (100.17mg, 0.34mmol), sodium carbonate (392.16mg, 3.70mmol) and [1,1'-bis(di Phenylphosphino)ferrocene]palladium dichloride (392.16 mg, 3.70 mmol) was dispersed in 1,4-dioxane (5 mL)/water (1 mL). The reaction mixture was purged with N2 and maintained at N2 atmosphere, slowly warmed up to 105°C and stirred overnight, then diluted with water, Extracted with ethyl acetate (50 mL ⁇ 2).
- Step 1 To a solution of 3,5-dichloropyridine-2-carbonitrile (1.0 g, 5.75 mmol) in methanol (25 mL) was added sodium methoxide (117.19 mg, 2.17 mmol) at 0°C. The reaction mixture was stirred at room temperature for 12 hours, concentrated, and water (15 mL) was added to the obtained concentrate, followed by extraction with ethyl acetate (45 mL).
- Step 3 According to the similar synthesis method of Step 2 in Example 2, Compound 50-3 was prepared using Compound 50-2 as a reactant.
- LCMS: m/z 351 [M+H] + .
- Step 4 Compound 50 (50 mg, 0.13 mmol, yield: 58%, purity: 98.29%) was prepared according to the similar synthesis method of step 3 in Example 2, using compound 50-3 as a reactant.
- MS (ESI): m/z 377 [M+H] + .
- Step 1 Compound 51-1 (46.42mg, 0.38mmol), pyridin-2-ylboronic acid (46.42mg, 0.38mmol), tetrakis(triphenylphosphine) palladium (29.09mg, 0.03mmol), Sodium bicarbonate (53.37 mg, 0.50 mmol) was dispersed in a mixed solvent of dimethyl sulfoxide (5 mL)/water (1 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 105° C., stirred overnight, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 2 Lithium hydroxide (0.47 g, 11.30 mmol) was added to a solution of compound 52-1 (1.5 g, 3.77 mmol) in THF (8 mL), water (4 mL), and methanol (2 mL) at room temperature .
- the reaction mixture was slowly heated to 60°C, stirred for 2 hours, concentrated, diluted with water, adjusted to pH below 4 with dilute hydrochloric acid (2N), and extracted with ethyl acetate (100 mL ⁇ 3).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 3 Add N,N-diisopropylethylamine (1.10 mL, 6.64 mmol) to compound 52-2 (850 mg, 2.21 mmol), methylamine hydrochloride (224.10 mg, 3.32 mmol) at room temperature and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1262.02mg, 3.32mmol) in N,N-dimethylformamide (15mL) solution. The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at room temperature overnight, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 4 Add compound 52-3 (200mg, 0.50mmol), 1-methyl-4-(tributylstannyl)-1H-imidazole (279.75mg, 0.75mmol), tetrakis(triphenylphosphine) at room temperature ) palladium (57.78 mg, 0.05 mmol) and cuprous iodide (10 mg, 0.05 mmol) were dispersed in N,N-dimethylformamide (4 mL).
- Step 2 To compound 53-1 (400mg, 1.58mmol), triethylamine (2.19mL, 15.77mmol) and To a solution (25 mL) of molecular sieves (200 mg) in ethanol was added hydroxylamine hydrochloride (547.83 mg, 7.88 mmol). The mixture was stirred and refluxed at 80°C for 12 hours. The mixture was concentrated, then water (15 mL) was added, extracted with ethyl acetate (45 mL), and washed with saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to obtain crude product.
- Step 3 Dissolve compound 53-2 (420mg, 1.46mmol), N,N'-carbonyldiimidazole (285mg, 1.76mmol) in tetrahydrofuran (10mL), react at 0°C for 30 minutes, then add 1,8 - Diazabicyclo[5.4.0]-7-undecene (0.33 mL, 2.20 mmol) was reacted at room temperature for 30 minutes.
- Step 1 Add N-iodosuccinimide (5.28g, 23.45mmol) to 3-fluoro-4-(trifluoromethyl)aniline (2.8g, 15.63mmol) at 0°C methane (40mL) solution.
- the reaction mixture was warmed to room temperature and stirred for 1 hour, diluted with water (30 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phases were concentrated.
- Step 2 Ethynyltrimethylsilane (1.62 mL, 11.41 mmol), triethylamine (1.32 mL, 9.51 mmol), cuprous iodide (0.09 mg, 0.68 mmol) and bis(triphenylphosphine) were chlorinated Palladium (0.33 g, 0,48 mml) was added to compound 56-1 (2.9 g, 9.51 mmol) in tetrahydrofuran (15 mL). The reaction mixture was purged with N2 and maintained under N2 atmosphere, stirred at room temperature for 3 hours, diluted with water (30 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phases were concentrated to give crude product.
- Step 5 To a methanol solution (10 mL) of compound 56-4 (150 mg, 0.49 mmol), triethylamine (0.68 mL, 4.91 mmol) and molecular sieves (100 mg) was added hydroxylamine hydrochloride (170.74 mg, 2.46 mmol). The reaction mixture was stirred at 80°C for 12 hours, concentrated, then added with water (15 mL), and extracted with ethyl acetate (45 mL). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
- Step 6 To a solution of compound 56-5 (136 mg, 0.40 mmol) in THF (5 mL) was added N,N'-carbonyldiimidazole (81.49 mg, 0.50 mmol) at 0°C. After the reaction mixture was stirred at room temperature for 30 minutes, 1,8-diazabicyclo[5.4.0]-7-undecene (90.01 ⁇ L, 0.60 mmol) was added and stirred for 1 hour, diluted with water (15 mL), Extract with ethyl acetate (45 mL). The combined organic phases were washed with saturated sodium chloride solution, dried and concentrated to obtain a crude product.
- N,N'-carbonyldiimidazole 81.49 mg, 0.50 mmol
- Step 2 Compound 59-1 (500mg, 1.6mmol), trimethylethynylsilane (240mg, 2.4mmol), Pd(PPh 3 ) 4 (184mg, 0.16mmol), CuI (30mg, 0.16mmol), DIPEA (412 mg, 3.2 mmol), and DMF (10 mL) were purged with N 2 and maintained under N 2 atmosphere, then stirred at 80° C. for 12 hours, added H 2 O (20 mL), and extracted with EA (30 mL). The combined organic phases were washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 6 Compound 59-5 (300mg, 0.9mmol), NH 2 OH ⁇ HCl (630mg, 9mmol), 10mL MeOH, TEA (3mL) and The mixture of molecular sieves (300 mg) was purged with N 2 and maintained under N 2 atmosphere, and after stirring at 80° C. for 3 hours, it was filtered under reduced pressure. After the filtrate was concentrated, H 2 O (20 mL) was added and extracted with EA (30 mL). The organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 7 CDI (57.3 mg, 0.35 mmol) was added to a solution of compound 59-6 (100 mg, 0.29 mmol) in THF (10 mL) under ice bath.
- the organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 1 N-iodosuccinimide (2.59 g, 11.50 mmol) was added to 3-chloro-4-(trifluoromethyl)aniline (1.5 g, 7.67 mmol) in acetic acid ( 20mL) solution.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed to room temperature, stirred for one hour, quenched with saturated sodium bicarbonate, and extracted with ethyl acetate (100 mL ⁇ 3).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 Add DIPEA (2.01 mL, 12.13 mmol) and ethynyltrimethylsilane (1.30 mL, 9.10 mmol) to compound 60-1 (1.95 g, 6.07 mmol), tetrakis(triphenylphosphine) at room temperature ) in a mixture of palladium (0.70g, 0.61mmol), cuprous iodide (0.12g, 0.61mmol) and DMF (25mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed to 80 °C and stirred overnight, then diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3).
- Step 3 Tetrabutylammonium fluoride (3.77 mL, 3.77 mmol) was added to a solution of compound 60-2 (1.0 g, 3.43 mmol) in THF (10 mL) at room temperature.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at room temperature for 30 min, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- MS (ESI): m/z 218 [MH] - .
- Step 4 Sodium tert-butoxide (1.02 g, 9.11 mmol) was added to a solution of compound 60-3 (1.0 g, 4.55 mmol) in NMP (10 mL) under ice-bath conditions. The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80° C., stirred for 2 hours, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 5 2-Chloronicotinonitrile (350 mg, 1.59 mmol) and Cs 2 CO 3 (1038.64 mg, 3.19 mmol) were sequentially added to a solution of compound 60-4 (350 mg, 1.59 mmol) in DMF (7 mL) at room temperature middle.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 120° C., stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 6 At room temperature, successively add hydroxylamine hydrochloride (907.26mg, 13.06mmol), Molecular sieves (420mg, 1.31mmol) and triethylamine (10.86mL, 78.34mmol) were added to a solution of compound 60-5 (420mg, 1.31mmol) in methanol (15mL), and the reaction mixture was purged with N2 and maintained under N2 Atmosphere, the temperature was slowly raised to 80° C., stirred for 3 hours, quenched with saturated ammonium chloride, filtered and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- hydroxylamine hydrochloride 907.26mg, 13.06mmol
- Molecular sieves 420mg, 1.31mmol
- triethylamine 10.86mL, 78.34mmol
- Step 7 Add CDI (257.13mg, 1.59mmol) to a solution of compound 60-6 (450mg, 1.27mmol) in tetrahydrofuran (5mL) under ice-bath conditions, stir at room temperature for 30 minutes, and again in ice-bath DBU (284.02 ⁇ L, 1.90 mmol) was added under conditions.
- the reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 According to the similar synthesis method of Step 1 in Example 3, compound 66-1 was prepared using 2-fluoro-3-methylbenzonitrile and 5-(trifluoromethyl)-1H-indole as reactants .
- LCMS: m/z 301 [M+H] + .
- Step 1 To a solution of 2,3-difluorobenzene-1-carbonitrile (0.4 mL, 3.59 mmol) and sodium tert-butoxide (414 mg, 4.31 mmol) in N,N-dimethylformamide (10 mL) was added 5-(Trifluoromethyl)-1H-indole (664.69 mg, 3.59 mmol). The reaction mixture was stirred at 120°C for 12 hours, diluted with water, and extracted with ethyl acetate (60 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain a crude product.
- Step 2 Hydroxylamine hydrochloride (342.60 mg, 4.93 mmol) was added to a mixture of compound 67-1 (300 mg, 0.99 mmol), triethylamine (1.37 mL, 9.86 mmol), molecular sieves (200 mg) and methanol (4 mL). The reaction mixture was stirred at 80°C for 12 hours and then concentrated. Water (15 mL) was added to the concentrate, followed by extraction with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a crude product.
- Step 3 Add N,N'-carbonyldiimidazole (70.66mg, 0.44mmol) to a tetrahydrofuran solution (5mL) of compound 67-2 (112mg, 0.35mmol) at 0°C, and stir at room temperature for 30 , 1,8-Diazabicyclo[5.4.0]-7-undecene (78.05 ⁇ L, 0.52 mmol) was added. The reaction mixture was stirred for 1 hour, diluted with water (15 mL), and extracted with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain a residue.
- Step 2 According to the similar synthesis method of Step 2 in Example 67, Compound 68-2 was prepared using Compound 68-1 as a reactant.
- LCMS: m/z 354 [M+H] + .
- Step 3 Compound 70 (86.17 mg, 0.25 mmol, yield 8.54%, purity: 99.6%) was prepared according to the similar synthesis method of Step 3 in Example 2, using compound 70-2 as a reactant.
- MS (ESI): m/z 348 [M+H] + .
- Step 1 To a solution of 4-chloropyrimidine-5-carbonitrile (1.0 g, 7.17 mmol) and sodium tert-butoxide (0.83 g, 8.60 mmol) in N,N-dimethylformamide (20 mL) was added 5- (Trifluoromethyl)-1H-indole (1.33 g, 7.17 mmol), and the reaction was stirred at 120° C. for 12 hours. The mixture was diluted with water (30 mL), extracted with ethyl acetate (90 mL), and washed with saturated sodium chloride solution. The combined organic layers were dried, filtered and concentrated to give crude product.
- Step 2 To compound 71-1 (380mg, 1.32mmol), triethylamine (1.83mL, 13.18mmol) and To a methanol solution (15 mL) of molecular sieves (380 mg) was added hydroxylamine hydrochloride (458.08 mg, 6.59 mmol). The mixture was stirred and refluxed at 80°C for 12 hours. After returning to room temperature, it was filtered, and the filtrate was concentrated, then water (15 mL) was added, extracted with ethyl acetate (45 mL), and washed with saturated sodium chloride solution. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to obtain crude product.
- hydroxylamine hydrochloride 458.08 mg, 6.59 mmol
- Step 3 Add N,N'-carbonyldiimidazole (70.66mg, 0.44mmol) to compound 71-2 (112mg, 0.35mmol) in tetrahydrofuran (5mL) at 0°C, and the mixture was stirred at room temperature for 30 minutes . Further 1,8-diazabicyclo[5.4.0]-7-undecene (78.05 ⁇ L, 0.52 mmol) was added to the mixture and stirred for 1 hour. The mixture was diluted with water (15 mL), extracted with ethyl acetate (45 mL), and washed with saturated ammonium chloride solution and saturated sodium chloride solution. The combined organic layers were dried, filtered and concentrated to give crude product.
- Step 3 Compound 72 (76.46 mg, 0.22 mmol, yield: 22.24%, purity 99.7%) was prepared according to the similar synthesis method of Step 3 in Example 2, using compound 72-2 as a reactant.
- MS (ESI): m/z 347 [M+H] + .
- Step 1 Add 5-(trifluoromethyl)indole (2.55g, 13.80mmol) and potassium tert-butoxide (3.10g, 27.59mmol) to 5-bromo-2-chloronicotinonitrile (3.00g, 13.80mmol ) in DMF (30 mL) solution.
- the reaction mixture was warmed up to 120° C. and stirred for 2 h, diluted with water (50 mL), and extracted with ethyl acetate (50 mL*3).
- Step 2 Trimethylboroxine (0.12mL, 0.44mmol, 3.5M in THF), potassium carbonate (452.94mg, 3.28mmol) and pd(dppf)Cl 2 (39.97mg, 0.05mmol) were added to Compound 75-1 (400mg, 1.09mmol) in dioxane (4mL) and water (0.5mL) mixed solution. The reaction mixture was heated to 100°C under nitrogen protection and stirred overnight, then filtered, and the resulting filtrate was diluted with water (10 mL), and extracted with ethyl acetate (10 mL*3).
- Step 4 At 0°C, CDI (0.03mL, 0.22mmol) was added to a solution of the crude product of compound 75-3 (60mg) in tetrahydrofuran (1mL), stirred at 0°C for 0.5h, then at 0°C DBU (0.04 mL, 0.27 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 1 h, diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3). The combined organic phases were concentrated, and the resulting residue was purified by preparative high-performance liquid chromatography (HPLC) to obtain compound 75 (13.47 mg, 0.04 mmol, yield 20.44%).
- HPLC preparative high-performance liquid chromatography
- Step 1 Add 5-(trifluoromethyl)indoline (810.55mg, 4.33mmol) and sodium tert-butoxide (416.17mg, 4.33mmol) to 2-chloronicotinonitrile (0.45mL, 4.33mmol) DMF (10mL) solution.
- the reaction mixture was warmed up to 80°C and stirred for 2 hours, diluted with water (30 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phases were concentrated to obtain a residue.
- Step 1 5-trifluoromethylindole (5.00g, 27.01mmol), compound 2-chloronicotinic acid ethyl ester (7.52g, 40.51mmol), Cs 2 CO 3 (17.60g, 17.60mmol) and DMF ( 20 mL) of the mixture was purged with N2 and maintained at N2 atmosphere, stirred at 120 °C for 3 h Afterwards, it was diluted with water (200 mL) and extracted with EA (50 mL). The organic phase was washed with saturated brine (20 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 1 Methyl 2-amino-2-methylpropanoate hydrochloride (226mg, 1.47mmol), HATU (647mg, 1.96mmol), DIPEA (759mg, 5.88mmol) and DMAP (12g, 0.10mmol) were added To a solution of compound 2-(5-trifluoromethyl)-1H-indol-1-ylnicotinic acid (300 mg, 0.98 mmol) in DMF (5 mL). The reaction mixture was stirred overnight at room temperature, and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 According to the similar synthesis method of Step 1 in Example 80, the compound 2-(5-trifluoromethyl)-1H-indol-1-ylnicotinic acid and 1-aminocyclopentane-1-carboxylic acid Methyl ester hydrochloride was used as a reactant to prepare compound 81-1.
- MS (ESI): m/z 432 [M+H] + .
- Step 1 To a solution of 2,5-dichloronicotinonitrile (1.0 g, 5.78 mmol) and sodium tert-butoxide (666.59 mg, 6.94 mmol) in N,N-dimethylformamide (15 mL) was added 5-( Trifluoromethyl)-1H-indole (1.07 g, 5.78 mmol). After the reaction mixture was stirred at 120°C for 12 hours, it was diluted with water (30 mL), and extracted with ethyl acetate (90 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain the crude product.
- Step 2 Hydroxylamine hydrochloride (540.04 mg, 7.77 mmol) was added to a mixture of compound 94-1 (500 mg, 1.55 mmol), triethylamine (2.15 mL, 15.54 mmol), molecular sieves (300 mg) and methanol (15 mL). The reaction mixture was stirred at 80 °C for 12 hours and then concentrated. Water (15 mL) was added to the concentrate, which was extracted with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a crude product.
- Step 3 Add N,N'-carbonyldiimidazole (142.85mg, 0.88mmol) to a solution of compound 94-2 (250mg, 0.70mmol) in tetrahydrofuran (8mL) at 0°C, and stir at room temperature for 30 minutes Afterwards, 1,8-diazabicyclo[5.4.0]-7-undecene (157.79 ⁇ L, 1.06 mmol) was added. The reaction mixture was stirred for 1 hour, diluted with water (15 mL), and extracted with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain the crude product.
- Step 1 To a mixture of compound 2-chloroquinoline-3-carbonitrile (1.88 g, 10 mmol) in 1-4 dioxane (20 mL) was added 5-trifluoromethylindole (2.2 g, 12 mmol), CuI (92mg, 0.5mmol), trans-(1R,2R)-N,N'-dimethyl 1,2-cyclohexanediamine (284mg, 2mmol), potassium phosphate (4.2g, 20mmol) the reaction mixture with N 2 purged and maintained N 2 atmosphere, after stirring at 110°C for 12 hours, diluted with H 2 O (200 mL), and extracted with EA (50 mL).
- Step 2 Compound 95-1 (1.3g, 4.26mmol), 20mL MeOH, NH 2 OH ⁇ HCl (2.9g, 42.6mmol), TEA (10mL) and The mixture of molecular sieves (1.3 g) was purged with N2 and maintained under N2 atmosphere, stirred at 80 °C for 3 hours, filtered under reduced pressure, and the filtrate was concentrated. The phase concentrate was added with H2O (20 mL) and extracted with EA (30 mL). The organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 1 To a mixture of compound 3-chloro-6,7-dihydro-5H-cyclopentane[c]pyridine-4-carbonitrile (1.78 g, 10 mmol) in 1-4Dioxane (20 mL) was added 5-trifluoroform Indole (2.2g, 12mmol), CuI (92mg, 0.5mmol), trans-(1R,2R)-N,N'-dimethyl 1,2-cyclohexanediamine (284mg, 2mmol), phosphoric acid Potassium (4.2 g, 20 mmol).
- Step 2 Compound 97-1 (1.3g, 4.26mmol), 20mL MeOH, NH 2 OH ⁇ HCl (2.9g, 42.6mmol), TEA (10mL) and The mixture of molecular sieves (1.3 g) was purged with N2 and maintained under N2 atmosphere, stirred at 80 °C for 3 hours, filtered under reduced pressure, and the filtrate was concentrated. After adding H2O (20 mL) to the concentrate, it was extracted with EA (30 mL). The organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 1 Disperse 2-aminonicotinonitrile (500mg, 4.20mmol), 1-chloro-2-nitro-4-trifluoromethylbenzene (0.63mL, 4.20mmol) and cesium carbonate (2735.00mg, 8.39mmol) in DMF (10 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed to 100°C and stirred for one hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 Add iron powder (956.57mg, 17.13mmol) and ammonium chloride (916.32mg, 17.13mmol) to compound 108-1 (880mg, 2.86mmol) in ethanol (12mL) and water (3mL) at room temperature in the solution.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80 °C and stirred for 2 hours, then filtered while hot.
- MS (ESI): m/z 279 [M+H] + .
- Step 4 At room temperature, successively add hydroxylamine hydrochloride (1205.46mg, 17.35mmol), Molecular sieves (500 mg, 2.23 mmol) and TEA (14.43 mL, 104.08 mmol) were added to a solution of compound 108-3 (500 mg, 1.73 mmol) in methanol (15 mL).
- the reaction mixture was purged with N2 and maintained under N2 atmosphere, slowly warmed up to 75 °C and stirred overnight, then quenched by adding saturated aqueous ammonium chloride solution, filtered and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 5 At room temperature, the crude product of compound 108-4 was dispersed in tetrahydrofuran (8 mL), and CDI (365.30 mg, 2.25 mmol) was added under ice-bath conditions, slowly raised to room temperature and stirred for 30 minutes, and then placed on ice DBU (403.50 ⁇ L, 2.70 mmol) was added under bath conditions, and the reaction system was slowly raised to room temperature and stirred for 1 hour. After the reaction was complete, the reaction system was diluted with water, and then extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- CDI 365.30 mg, 2.25 mmol
- Step 1 5-(Trifluoromethyl)-1H-pyrrole[2,3-b]pyridine (806 mg, 4.33 mmol) and sodium tert-butoxide (416.17 mg, 4.33 mmol) were added to 2-chloronicotinonitrile ( 0.45 mL, 4.33 mmol) in DMF (10 mL). The reaction mixture was warmed up to 80°C and stirred for 2 hours, diluted with water (30 mL), and extracted with ethyl acetate (20 mL*3). The combined organic phases were concentrated to give a residue.
- Step 2 Hydroxylamine hydrochloride (807.66mg, 11.62mmol), TEA (6.44mL, 46.49mmol) and Molecular sieve (100mg) plus into a solution of compound 111-1 (670 mg, 2.32 mmol) in methanol (10 mL). The reaction mixture was warmed up to 80°C and stirred for 2 hours, then filtered. The resulting filtrate was concentrated, diluted with water (30 mL), and extracted with ethyl acetate (30 mL*3). The combined organic phases were concentrated to obtain a residue.
- Step 3 Add CDI (0.13mL, 1.05mmol) to a solution of compound 111-2 (270mg, 0.84mmol) in tetrahydrofuran (2mL) at 0°C, stir at 0°C for 0.5 hours, then add DBU (0.19mL, 1.26 mmol), warmed to room temperature and stirred for 1 hour, diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3). The combined organic phases were concentrated to obtain a residue. The obtained residue was purified by preparative high-performance liquid chromatography (HPLC) to obtain compound 111 (15.47 mg, 0.04 mmol, yield: 5.29%).
- HPLC high-performance liquid chromatography
- Step 1 At room temperature, successively dissolve 2-iodo-4-trifluoromethylaniline (1.0g, 3.48mmol) in propyne (8mL) and DMF (1mL) and add cuprous iodide (0.07g, 0.35mmol), bistriphenylphosphinepalladium dichloride (0.12g, 0.17mmol) and triethylamine (3mL, 21.64mmol).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80 °C and stirred for 16 hours, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- the resulting residue was purified by silica gel column chromatography (eluted with petroleum ether) to obtain compound 113-1 (677 mg, yield: 97.56%).
- MS (ESI): m/z 200 [M+H
- Step 2 Potassium tert-butoxide (381.39 mg, 3.40 mmol) was added to a solution of compound 113-1 (677 mg, 3.40 mmol) in NMP (8 mL) at room temperature. The reaction mixture was slowly warmed to 80°C and stirred for 2 hours, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue. The resulting residue was purified by silica gel column chromatography (eluted with petroleum ether) to obtain compound 113-2 (380 mg, yield: 56.13%).
- Step 4 At room temperature, hydroxylamine hydrochloride (359.82mg, 5.18mmol), Molecular sieves (160 mg, 2.23 mmol), and triethylamine (4.31 mL, 31.07 mmol) were sequentially added to a solution of compound 113-3 (156 mg, 0.52 mmol) in methanol (5 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 75 °C, stirred overnight, quenched with saturated ammonium chloride, and filtered. The resulting filtrate was extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 5 Add CDI (101.86mg, 0.63mmol) to a solution of compound 113-4 (168mg, 0.50mmol) in tetrahydrofuran (3mL) under ice bath conditions, slowly rise to room temperature and stir for 30min, then again in ice bath DBU (112.51 ⁇ L, 0.75 mmol) was added under conditions. The reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 According to the similar synthesis method of step 1 in Example 67, compound 114-1 was prepared using 2-chloro-4-methylbenzonitrile and 5-(trifluoromethyl)-1H-indole as reactants .
- MS (ESI): m/z 301 [M+H] + .
- Step 1 At room temperature, mix 2-chloro-4-methylnicotinonitrile (200mg, 1.31mmol), 5-(trifluoromethyl)-1H-indole (242.69mg, 1.31mmol) and cesium carbonate (854.16 mg, 2.62mmol) was dispersed in DMF (5mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 100° C., stirred for 1 hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 At room temperature, successively add hydroxylamine hydrochloride (369.05mg, 5.31mmol), Molecular sieves (160 mg, 2.23 mmol) and triethylamine (4.42 mL, 31.87 mmol) were added to a solution of compound 116-1 (160 mg, 0.53 mmol) in methanol (8 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, the temperature was slowly raised to 75 °C, stirred overnight, quenched by adding saturated ammonium chloride, and filtered.
- Step 3 Add CDI (75.79mg, 0.47mmol) to a solution of compound 116-2 (125mg, 0.37mmol) in tetrahydrofuran (3mL) under ice bath conditions, stir at room temperature for 30min, and again under ice bath conditions DBU (83.71 ⁇ L, 0.56 mmol) was added at the bottom.
- the reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 According to the similar synthesis method of Step 1 in Example 116, compound 117-1 was prepared using 2-chloro-5-methoxynicotinonitrile and 5-(trifluoromethyl)-1H-indole as reactants .
- MS (ESI): m/z 318 [M+H] + .
- Step 3 Compound 117 (50 mg, 0.13 mmol, yield: 58%, purity: 98.29%) was prepared according to the similar synthesis method of step 3 in Example 116, using compound 117-2 as a reactant.
- MS (ESI): m/z 377 [M+H] + .
- Step 1 2-Chloro-5-fluoronicotinonitrile (250mg, 1.60mmol), 5-(trifluoromethyl)-1H-indole (296.24mg, 1.60mmol) and cesium carbonate (1042.62mg , 3.20mmol) was dispersed in DMF (5mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 120° C., stirred for 1 hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 At room temperature, successively add hydroxylamine hydrochloride (182.13mg, 2.62mmol), Molecular sieves (80 mg, 0.26 mmol) and triethylamine (2.18 mL, 15.73 mmol) were added to a solution of compound 118-2 (80 mg, 0.26 mmol) in methanol (3 mL).
- the reaction mixture was purged with N 2 and the N 2 atmosphere was maintained, the temperature was slowly raised to 80°C and stirred for 3 hours, the reaction solution was quenched with saturated ammonium chloride and filtered.
- Step 3 Add CDI (100.06mg, 0.62mmol) to a solution of compound 118-2 (167mg, 0.49mmol) in tetrahydrofuran (3mL) under ice-bath conditions, stir at room temperature for 30 minutes, and again in ice-bath DBU (110.53 ⁇ L, 0.74 mmol) was added under conditions.
- the reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 To 5-bromo-2-[5-(trifluoromethyl)indol-1-yl]pyridine-3-carbonitrile (400mg, 1.09mmol), potassium carbonate (301.96mg, 2.18mmol) and bis [5-(Diphenylphosphino)cyclopent-1,3-dienyl]- ⁇ 2-iron(II)palladium chloride (79.94 mg, 0.11 mmol) in 1,4-dioxane (10 mL) Ethylboronic acid (80.72mg, 1.09mmol) was added to the mixed solution with water (2mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at 90° C.
- Step 2 Hydroxylamine hydrochloride (104.69 mg, 2.14 mmol) was added to a mixture of compound 119-1 (135 mg, 0.43 mmol), triethylamine (0.42 mL, 4.28 mmol), molecular sieves (100 mg), and methanol (10 mL) .
- the reaction mixture was stirred at 80 °C for 3 hours and then concentrated.
- Water (15 mL) was added to the obtained concentrate, and extracted with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 3 Disperse the crude product of compound 119-2 (123mg) and N,N'-carbonyldiimidazole (71.57mg, 0.44mmol) in tetrahydrofuran (5mL), react at 0°C for 30 minutes, then add 1, 8-Diazabicyclo[5.4.0]-7-undecene (79.06 ⁇ L, 0.53 mmol). After reacting the reaction mixture at room temperature for 1 hour, it was quenched with water (15 mL), and extracted with ethyl acetate (15 mL ⁇ 3). The combined organic phases were washed with water and concentrated to obtain a residue.
- Step 1 Mix 5-bromo-2-chloronicotinonitrile (3.00g, 13.80mmol), sodium tert-butoxide (1.59g, 16.56mmol), 5-(trifluoromethyl)-1H-indole (2.55g, 13.80 mmol), and N,N-dimethylformamide (30 mL) were stirred at 120° C. for 3 hours, diluted with water (40 mL), and extracted with ethyl acetate (120 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain a crude product.
- Step 2 Hydroxylamine hydrochloride (759.16 mg, 10.92 mmol) was added to a mixture of compound 121-1 (800 mg, 2.18 mmol), triethylamine (3.03 mL, 21.85 mmol), molecular sieves (500 mg), and methanol (30 mL) .
- the reaction mixture was stirred at 80 °C for 12 hours and then concentrated.
- Water (20 mL) was added to the obtained concentrate, and extracted with ethyl acetate (60 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a crude product.
- Step 4 Zinc cyanide (181.17 mg, 1.54 mmol) was added to compound 121-3 (164 mg, 0.39 mmol) and tetrakis(triphenylphosphine) palladium (89.15 mg, 0.08 mmol), and N,N-dimethyl in a mixture of methyl formamide solution (1.9 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, then stirred at 120° C. for 12 hours, water (10 mL) was added, and extracted with ethyl acetate (30 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 5-(trifluoromethyl)-1H-indole (1.19g, 6.42mmol) was added to the crude product of compound 122-1 (1.07g, 6.42mmol), sodium tert-butoxide (0.8g, 7.06 mmol) and N,N-dimethylformamide (15 mL). After the reaction mixture was stirred at 120°C for 1.5 hours, it was diluted with water (30 mL), and extracted with ethyl acetate (90 mL). The organic phase was washed with saturated sodium chloride solution, dried and concentrated to obtain a crude product.
- Step 3 Hydroxylamine hydrochloride (550.98 mg, 7.93 mmol) was added to a mixture of compound 122-2 (500 mg, 1.59 mmol), triethylamine (2.2 mL, 15.86 mmol), molecular sieves (300 mg) and methanol (15 mL). After the reaction mixture was stirred at 80°C for 12 hours, water (15 mL) was added, and extracted with ethyl acetate (45 mL). The organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated to obtain a crude product.
- Step 4 Add N,N'-carbonyldiimidazole (200.17mg, 1.23mmol) to a solution of compound 122-3 (344mg, 0.99mmol) in tetrahydrofuran (10mL) under ice bath conditions, and react at 0°C After 30 minutes 1,8-diazabicyclo[5.4.0]-7-undecene (221.1 ⁇ L, 1.48 mmol) was added. After reacting the reaction mixture at room temperature for 1 hour, it was quenched with water (15 mL), and extracted with ethyl acetate (15 mL ⁇ 3). The combined organic phases were washed with water, dried and concentrated to obtain a residue.
- Step 3 Add CDI (36.5mg, 0.22mmol) to a THF (2mL) solution of compound 123-2 (83mg, 0.28mmol) at 0°C, warm to room temperature and stir for 30 minutes, then add DBU (41 ⁇ L, 0.27 mmol). The reaction mixture was warmed to room temperature, stirred for 1 hour and then concentrated. Saturated ammonium chloride solution (2 mL) was added to the resulting concentrate to quench the reaction, and extracted with EA (20 mL). The organic phase was washed with saturated brine (3 times), dried and concentrated to obtain a residue.
- Step 1 At room temperature, 2-chloro-6-methylnicotinonitrile (300mg, 1.97mmol), 5-(trifluoromethyl)-1H-indole (364.04mg, 1.97mmol) and cesium carbonate ( 1281.24 mg, 3.93 mmol) was dispersed in DMF (8 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed slowly to 120° C. and stirred for 1 h, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 2 At room temperature, successively add hydroxylamine hydrochloride (1314.74mg, 18.92mmol), Molecular sieves (675 mg, 2.23 mmol) and TEA (15.74 mL, 113.52 mmol) were added to a solution of compound 124-1 (570 mg, 1.89 mmol) in methanol (20 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 75 °C, stirred overnight, quenched with saturated ammonium chloride, and filtered.
- the resulting filtrate was extracted with ethyl acetate (50 mL ⁇ 2), and the combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 3 Add CDI (121.26mg, 0.75mmol) to a solution of compound 124-2 (200mg, 0.60mmol) in tetrahydrofuran (5mL) under ice bath conditions, stir at room temperature for 30min, and again under ice bath conditions DBU (0.13 mL, 0.90 mmol) was added at the same time.
- the reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 1 Disperse 5-bromo-2-chloronicotinonitrile (500mg, 2.30mmol), 5-trifluoromethylindole (425.73mg, 2.30mmol) and cesium carbonate (1498.37mg, 4.60mmol) in DMF (10mL )middle.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed up to 120 °C and stirred for 1 hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3).
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 2 Compound 126-1 (1130mg, 3.09mmol), pinacol diboronate (1175.58mg, 4.63mmol), potassium acetate (605.77mg, 6.17mmol) and Pd(dppf)Cl 2 were sequentially mixed at room temperature (225.82 mg, 0.31 mmol) was dispersed in 1,4-dioxane (20 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 95 °C, stirred overnight, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated.
- Step 3 Compound 126-2 (1.1 g, 2.66 mmol), 2-fluorobromomethylbenzene (0.38 mL, 3.19 mmol), potassium carbonate (0.74 g, 5.32 mmol) and Pd(dppf)Cl were mixed at room temperature 2 (0.19g, 0.27mmol) was dispersed in a mixed solvent of acetonitrile (20mL) and water (4mL). mix the reaction The mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed up to 80 °C and stirred overnight, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 3).
- Step 4 At room temperature, successively add hydroxylamine hydrochloride (790.94mg, 11.38mmol), Molecular sieves (450 mg, 2.23 mmol), and TEA (9.47 mL, 68.29 mmol) were added to a solution of compound 126-3 (450 mg, 1.14 mmol) in methanol (15 mL).
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed to 75 °C and stirred overnight, quenched with saturated ammonium chloride, filtered and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 5 Add CDI (149.51mg, 0.92mmol) to a solution of compound 126-4 (316mg, 0.74mmol) in tetrahydrofuran (3mL) under ice-bath conditions, slowly rise to room temperature and stir for 30min. DBU (165.15 ⁇ L, 1.11 mmol, 1 mL) was added under conditions. The reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 1 To a mixture of compound 5-bromo-2-chloronicotinonitrile (2.14 g, 10 mmol) in DMF (20 mL) was added 5-trifluoromethylindole (2.2 g, 12 mmol) and sodium tert-butoxide (1.9 g ,20mmol). The reaction mixture was stirred at 80 °C for 3 h, diluted with H2O (200 mL), and extracted with EA (50 mL). The organic phase was washed with saturated brine (20 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated to obtain a residue.
- Step 2 Compound 127-1 (1.8g, 5mmol), 3-hydroxypyrrolidine (560mg, 6.5mmol) Pd 2 (dba) 3 (450mg, 0.5mmol), XantPhos (570mg, 1mmol), and 1-4
- the mixture of dioxane (20 mL) was stirred at 80°C for 12 hours and then concentrated.
- MS (ESI): m/z 373 [M+H] + .
- Step 3 Compound 127-2 (1 g, 2.7 mmol), MeOH (20 mL), NH 2 OH ⁇ HCl (1.8 g, 27 mmol), TEA (10 mL) and The mixture was purged with N2 and maintained under N2 atmosphere, after stirring at 80 °C for 3 h, it was filtered under reduced pressure. The resulting filtrate was concentrated, added H 2 O (20 mL), and extracted with EA (30 mL). The organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated.
- Step 5 Compound 128-4 (315 mg, 0.96 mmol), MeOH (20 mL), NH 2 OH ⁇ HCl (672 mg, 9.6 mmol), TEA (15 mL) and The mixture was purged with N2 and maintained under N2 atmosphere, stirred at 80 °C for 3 h and then filtered under reduced pressure. H2O (20 mL) was added to the resulting filtrate and extracted with EA (30 mL).
- Step 4 Compound 129-3 (570 mg, 2.93 mmol), 5-trifluoromethylindole (542.26 mg, 2.93 mmol) and cesium carbonate (1908.51 mg, 5.86 mmol) were dispersed in DMF (10 mL) at room temperature middle. The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80° C., stirred for 1 hour, diluted with water, and extracted with ethyl acetate (100 mL ⁇ 2).
- Step 5 At room temperature, hydroxylamine hydrochloride (1522.14mg, 21.90mmol), Molecular sieves (760 mg, mmol), and triethylamine (18.22 mL, 131.43 mmol) were added to a solution of compound 129-4 (752 mg, 2.19 mmol) in methanol (20 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80 °C and stirred for 3 hours, quenched with saturated ammonium chloride and filtered. The resulting filtrate was extracted with ethyl acetate (50 mL ⁇ 2), and the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a residue.
- Step 6 Add CDI (262.82mg, 1.62mmol) to a solution of compound 129-5 (488mg, 1.30mmol) in tetrahydrofuran (8mL) under ice-bath conditions, slowly rise to room temperature and stir for 30min. DBU (290.31 ⁇ L, 1.95 mmol) was added at the same time. The reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2). The combined organic phases were dried over anhydrous sodium sulfate and concentrated, and the resulting residue was purified by silica gel column chromatography (ethyl acetate) to obtain compound 129 (15 mg, yield: 2.87%).
- Step 3 At room temperature, di-tert-butyl dicarbonate (0.41 mL, 1.94 mmol) was added dropwise to a solution of compound 130-2 (375 mg, 1.94 mmol) in tetrahydrofuran (5 mL) and water (2.5 mL), followed by Sodium carbonate (205.27 mg, 1.94 mmol) was added.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at 28 °C for 12 h, concentrated, and extracted with dichloromethane (20 mL ⁇ 2).
- Step 4 5-Trifluoromethylindole (94.54 mg, 0.51 mmol) and cesium carbonate (166.38 mg, 0.51 mmol) were added to compound 130-3 (150 mg, 0.51 mmol) in DMF (2 mL) at room temperature in solution.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80 °C and stirred for 1 hour, diluted with water, and extracted with ethyl acetate (20 mL ⁇ 2).
- Step 5 At room temperature, hydroxylamine hydrochloride (133.50mg, 1.92mmol), Molecular sieves (90 mg, mmol) and triethylamine (1.60 mL, 11.53 mmol) were added to a solution of compound 130-4 (85 mg, 0.19 mmol) in methanol (2 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, slowly warmed to 75 °C and stirred for 3 hours, quenched by adding saturated ammonium chloride, filtered, and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 6 Add CDI (23.87mg, 0.15mmol) to compound 130-5 (56mg, 0.12mmol) in tetrahydrofuran (1mL) under ice-bath conditions, slowly warm up to room temperature and stir for 30min, then under ice-bath conditions DBU (26.37 ⁇ L, 0.18 mmol) was added. The reaction mixture was slowly warmed to room temperature, stirred for 1 hour, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
- Step 1 Add 5-trifluoromethylindole (2, 159mg, 0.86mmol) and t- Sodium butoxide (83 mg, 0.86 mmol).
- the reaction mixture was purged with N2 and maintained under N2 atmosphere, after stirring at 80 °C for 3 h, cooled to 25 °C, quenched with saturated ammonium chloride solution (5 mL), and extracted with EA (40 mL).
- Step 3 Add CDI (31mg, 0.19mmol) to compound 131-2 (55mg, 0.15mmol) in THF (2mL) at 0°C, warm to room temperature and stir for 30 minutes, then add DBU at 0°C (34 ⁇ L, 0.22 mmol). The reaction mixture was warmed to room temperature and stirred for 1 hour, then concentrated, the mixture was quenched by adding saturated ammonium chloride solution (2 mL), and extracted with EA (20 mL).
- Step 2 Compound 133-1 (461.7 mg, 1.43 mmol), MeOH (21 mL), NH 2 OH ⁇ HCl (994.3 mg, 14.31 mmol), TEA (13 mL) and The mixture was purged with N2 and maintained under N2 atmosphere, stirred at 80 °C for 2 h, filtered under reduced pressure, and the resulting filtrate was concentrated. H 2 O (20 mL) was added to the obtained concentrate, followed by extraction with EA (30 mL). The organic phase was washed with saturated brine (10 mL ⁇ 3), dried over anhydrous Na 2 SO 4 and concentrated.
- Step 4 Aqueous solution (0.2 mL) of Na 2 CO 3 (41.7 mg, 323.40 mmol) was added to compound 133-3 (75.0 mg, 0.20 mmol), 1,4-dioxane (1.2 mL), vinyl In a mixture of pinacol borate (45.4mg, 0.29mmol) and Pd(dppf)Cl 2 (14.3mg, 0.02mmol). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at 100° C. for 12 h, diluted with H 2 O (2 mL), and extracted with EA (5 mL).
- Step 1 Na 2 CO 3 (38.3 mg, 0.36 mmol) in water (0.2 mL H 2 O) was added to compound 133-3 (70.0 mg, 0.18 mmol), 1,4-dioxane (1.2 mL), 4,4,5,5-Tetramethyl-2-propen-2-yl-1,3,2-dioxaborinane (60.7mg, 0.36mmol) and Pd(dppf)Cl 2 (13.2mg, 0.02 mmol) in the mixture.
- the reaction mixture was purged with N 2 and maintained under N 2 atmosphere, stirred at 100° C. for 12 h, diluted with H 2 O (2 mL), and extracted with EA (5 mL).
- Step 2 A mixture of compound 134-1 (15.0 mg, 0.04 mmol), THF (0.2 mL), MeOH (0.5 mL) and Pd/C (5%) (3.0 mg) was purged with H2 and maintained under H2 Atmosphere, after stirring at room temperature for 4 hours, purged with N2 and maintained N2 atmosphere, filtered under reduced pressure. The filtrate obtained by filtration and the filtrate obtained by washing the filter cake with DCM, EA, and MeOH successively were combined, dried over anhydrous Na 2 SO 4 , and concentrated to obtain a residue.
- Step 3 Slowly add NaH (48 mg, 1.2 mmol) to a solution of compound 136-2 (100 mg, 0.59 mmol) in DMF (5 mL), react at room temperature for 1 hour, add 5-trifluoromethylindole (130 mg , 0.7 mmol). The reaction mixture was stirred at 120 °C for 3 h, diluted with H2O (200 mL), and extracted with EA (50 mL).
- Step 4 Compound 136-3 (176 mg, 0.55 mmol), MeOH (20 mL), NH 2 OH ⁇ HCl (388 mg, 5.5 mmol), TEA (10 mL) and The mixture was purged with N2 and maintained under N2 atmosphere, after stirring at 80 °C for 3 h, it was filtered under reduced pressure. The obtained filtrate was concentrated, and H 2 O (20 mL) was added to the obtained concentrate, extracted with EA (30 mL).
- 1 H NMR 400MHz, DMSO-d6) ⁇ 8.12(s, 2H), 7.87(s, 1H).
- Step 2 5-(Trifluoromethyl)-indole (4.14 g, 4.33 mmol) and sodium tert-butoxide (2.15 g, 22.39 mmol) were added to compound 137-1 (3.46 g, 22.39 mmol) in DMF ( 40mL) solution.
- the reaction mixture was stirred at 80°C for 2 hours, diluted with water (100 mL), and extracted with ethyl acetate (100 mL*3).
- Step 4 Add CDI (114.52mg, 0.71mmol) to a solution of compound 137-3 (190mg, 0.57mmol) in tetrahydrofuran (2mL) at 0°C, stir at room temperature for 0.5 hours, then add DBU (0.13 mL, 0.85 mmol). After the reaction mixture was stirred at room temperature for 1 hr, it was diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3). The combined organic phases were concentrated and the resulting residue was purified by preparative high performance liquid chromatography (HPLC) to afford compound 137-4. (45.47 mg, 0.12 mmol, yield: 21.31%, purity: 96.04%).
- HPLC preparative high performance liquid chromatography
- Step 5 Add copper chloride (38.97 mg, 0.29 mmol) and tert-butyl nitrite (0.03 mL, 0.29 mmol) to a solution of compound 137-4 (70 mg, 0.19 mmol) in acetonitrile (1 mL) at 0 °C middle. After the reaction mixture was stirred at 50°C for 16 hours, it was diluted with water (3 mL), and extracted with ethyl acetate (3 mL*3). The combined organic phases were concentrated, and the obtained crude product was purified by preparative high-performance liquid chromatography (HPLC) to obtain compound 137 (2.88 mg, 0.01 mmol, yield: 3.89%, purity: 99.65%).
- HPLC preparative high-performance liquid chromatography
- Step 1 According to the similar synthesis method of Step 1 in Example 118, 3-chloro-5-trifluoromethylpyrazine-2-carbonitrile and 5-trifluoromethyl-1H- Indole was used as a reactant to prepare compound 138-1.
- MS (ESI): m/z 357 [M+H] + .
- Step 1 At room temperature, mix 5-bromo-3-(5-(trifluoromethyl)-1H-indol-1-yl)pyrazine-2-carbonitrile (50mg, 0.14mmol), ethylboronic acid (50 mg, 0.68 mmol), potassium carbonate (56 mg, 0.41 mmol) and Pd(dppf)Cl 2 (28 mg, 0.07 mmol) were dispersed in 1,4-dioxane (1 mL)/water (0.1 mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 80 °C and stirred overnight, diluted with water, and extracted with ethyl acetate (10 mL ⁇ 3).
- Step 6 Under nitrogen atmosphere, to compound 144-5 (100mg, 0.56mmol), 5-trifluoromethyl-1H-indole (123.32mg, 0.67mmol), trans-N-dimethylcyclohexane - To a solution of 1,2-diamine (165mg, 1.16mmol) and potassium phosphate (117.82mg, 0.56mmol) in toluene (6mL) was added cuprous iodide (100mg, 0.53mmol). The reaction mixture was stirred overnight at 110 °C, diluted with H2O , and extracted with EA.
- Step 8 Add CDI (58.92mg, 0.36mmol) to a THF (4mL) solution of compound 144-7 (72mg, 0.18mmol) at 0°C, stir at room temperature for 1 hour, then add DBU (54.23 ⁇ L, 0.36 mmol). The reaction mixture was stirred at room temperature for 1.5 hours, cooled to 0 °C, adjusted to pH 6 with hydrochloric acid (2M), diluted with water, and extracted with EA. The organic phase was washed with saturated brine, dried and concentrated, and the resulting residue was purified by silica gel column chromatography to obtain compound 144 (16 mg, 0.04 mmol, yield: 20.86%).
- Step 3 Add 5-(trifluoromethyl)-1H-indole (132.36mg, 0.71mmol) to a solution of compound 146-2 (107mg, 0.60mmol) in toluene (2mL), BrettPhos Pd G3 (54.01mg, 0.06mmol) and sodium tert-butoxide (85.88mg, 0.89mmol). After stirring the reaction mixture at 100 °C for 18 hours. Poured into water (3 mL), and extracted with ethyl acetate (5 mLx3).
- Step 5 At 0° C., CDI (11.23 mg, 0.07 mmol) was added to a solution of the crude product (35 mg) of compound 146-4 in THF (6 mL), and after stirring at 0° C. for 1 hour, DBU ( 14.11 ⁇ L, 0.09 mmol). After the reaction mixture was stirred at 0° C. for 1 hour, it was poured into water (6 mL), and extracted with ethyl acetate (6 mL ⁇ 3). The combined organic phases were washed with hydrochloric acid (1M), dried over anhydrous sodium sulfate and concentrated, and the resulting residue was purified by high performance liquid chromatography to obtain compound 146 (3.16 mg, yield: 11.93%).
- Step 9 Compound 147-8 (1g, 5.16mmol), 5-(trifluoromethyl)-1H-indole (1.15g, 6.20mmol), and Breetphos G3 (468.17mg, 0.52mmol) were dispersed in toluene ( 20mL).
- the reaction mixture was purged with N2 and maintained under N2 atmosphere, after stirring at 100 °C for 12 h, water was added and extracted with ethyl acetate.
- the combined organic phases were dried over anhydrous sodium sulfate and concentrated, and the resulting residue was purified by silica gel column chromatography to obtain compound 147-9 (389 mg, yield: 22%).
- MS (ESI): m/z 343 [M+H] + .
- Step 5 Add 5-trifluoromethyl-1H-indole (344.98 mg, 1.86 mmol), cuprous iodide (202.83 mg, 1.06mmol), trans-N,N-dimethylcyclohexane-1,2-diamine (66.85mg, 0.47mmol) and potassium phosphate (329.58mg, 1.55mmol).
- the reaction mixture was stirred overnight at 110 °C, cooled to room temperature, diluted with H2O , and extracted with EA. The organic phase was washed with saturated brine (3 times), dried and concentrated, and the resulting residue was purified by silica gel column chromatography to obtain compound 150-5 (280 mg, 0.74 mmol, yield: 47.79%).
- MS (ESI): m/z 378 [M+H] + .
- Step 7 Add CDI (148.18 mg, 0.91 mmol) to a THF (8 mL) solution of compound 150-6 (230 mg, 0.61 mmol) at 0°C, stir at room temperature for 0.5 hours, then add DBU (163.68 ⁇ L, 1.10 mmol). The reaction mixture was stirred at room temperature for 1.5 hours, cooled to 0 °C and adjusted to pH 6 with hydrochloric acid (2M), diluted with water, and extracted with EA. The organic phase was washed with saturated brine, dried and concentrated, and the resulting residue was purified by silica gel column chromatography to obtain compound 150 (57 mg, 0.13 mmol, yield: 21.44%).
- Step 1 At room temperature, tert-butyl carbamate (740.69mg, 6.32mmol), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (Xantphos) (997.75mg, 1.72mmol ), cesium carbonate (3745.49mg, 11.50mmol) and palladium acetate (129.04mg, 0.57mmol) were added to 3,6-dichloropyrazine-2-carbonitrile (0.63mL, 5.75mmol) in 1,4 dioxane ring (25 mL).
- Xantphos 4,5-bisdiphenylphosphine-9,9-dimethylxanthene
- Step 2 Compound 155-1 (600mg, 2.36mmol), 5-trifluoromethyl-1H-indole (436.21mg, 2.36mmol), cesium carbonate (1535.26mg, 4.71mmol) were dispersed in DMF at room temperature (10mL). The reaction mixture was purged with N 2 and maintained under N 2 atmosphere, warmed up slowly to 120 °C and stirred for 8 hours, diluted with water, and extracted with ethyl acetate (50 mL ⁇ 2).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne un composé tricyclique représenté par la formule (O), une composition pharmaceutique comprenant le composé en tant que principe actif, et une application de celui-ci. Le composé est un excellent inhibiteur de TEAD et peut être utilisé pour traiter des tumeurs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202380019299.2A CN118715221A (zh) | 2022-01-30 | 2023-01-19 | 三环化合物及其应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210113616.4 | 2022-01-30 | ||
CN202210113616 | 2022-01-30 | ||
CN202211572946 | 2022-12-08 | ||
CN202211572946.6 | 2022-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023143354A1 true WO2023143354A1 (fr) | 2023-08-03 |
Family
ID=87470770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/073087 WO2023143354A1 (fr) | 2022-01-30 | 2023-01-19 | Composé tricyclique et son application |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN118715221A (fr) |
TW (1) | TW202340180A (fr) |
WO (1) | WO2023143354A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020081572A1 (fr) * | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs du facteur de transcription à domaine associé transcriptionnel amélioré (tead) et leurs utilisations |
CN111132673A (zh) * | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
CN111542315A (zh) * | 2017-08-21 | 2020-08-14 | 维瓦斯治疗公司 | 苯并磺酰基化合物 |
WO2020243415A2 (fr) * | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
WO2020243423A1 (fr) * | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
-
2023
- 2023-01-19 WO PCT/CN2023/073087 patent/WO2023143354A1/fr unknown
- 2023-01-19 CN CN202380019299.2A patent/CN118715221A/zh active Pending
- 2023-01-19 TW TW112102666A patent/TW202340180A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111132673A (zh) * | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
CN111542315A (zh) * | 2017-08-21 | 2020-08-14 | 维瓦斯治疗公司 | 苯并磺酰基化合物 |
WO2020081572A1 (fr) * | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs du facteur de transcription à domaine associé transcriptionnel amélioré (tead) et leurs utilisations |
WO2020243415A2 (fr) * | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
WO2020243423A1 (fr) * | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
TW202340180A (zh) | 2023-10-16 |
CN118715221A (zh) | 2024-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109879859B (zh) | Cot调节剂及其使用方法 | |
TWI423962B (zh) | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 | |
CN103420977B (zh) | 具有抗肿瘤活性的乙炔衍生物 | |
WO2016026445A1 (fr) | Composés indazole utilisés comme inhibiteurs de la fgfr kinase, préparation et utilisation associées | |
WO2018113584A1 (fr) | Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique | |
CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
CN113454085A (zh) | Mat2a的aza杂双环抑制剂和用于治疗癌症的方法 | |
CN108026067A (zh) | 作为cot调节剂的6-氨基-喹啉-3-腈 | |
WO2023098439A1 (fr) | Dérivé de pyrazole, son procédé de préparation et son utilisation en médecine | |
WO2018010514A1 (fr) | Composé hétérocyclique utilisé en tant qu'inhibiteur de fgfr | |
CN104109166B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
WO2021175283A1 (fr) | Synthèse d'un nouvel antagoniste d'ep4 et utilisation dans des cancers et des inflammations | |
WO2020143763A1 (fr) | Composés d'halogénoallylamine et leur utilisation | |
WO2023280237A1 (fr) | Synthèse et utilisation d'agent de dégradation de phosphatase | |
TW201917129A (zh) | 含吡唑基的三并環類衍生物、其製備方法和應用 | |
CN114437074A (zh) | 一种化合物、含该化合物的药物组合物及其用途 | |
WO2022127199A1 (fr) | Composés polycycliques pour inhiber l'arn hélicase dhx33 et leur utilisation | |
TW202313048A (zh) | 組合療法 | |
TW202214615A (zh) | 一種egfr抑制劑及其製備方法和應用 | |
WO2023142641A1 (fr) | Dérivé de pyridine, son procédé de préparation et son utilisation | |
WO2023036252A1 (fr) | Dérivé de pyrrolopyrimidine ou de pyrrolopyridine et son utilisation médicale | |
TW202043209A (zh) | Mek抑制劑及其在醫藥上的應用 | |
WO2023169573A1 (fr) | Inhibiteur de polθ | |
WO2023143354A1 (fr) | Composé tricyclique et son application | |
WO2023125841A1 (fr) | COMPOSÉ HÉTÉROCYCLIQUE EN TANT QU'INHIBITEUR DE POLθ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23746235 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |